Prerpints.org logo
Preprint
Review

This version is not peer-reviewed.

The Role of the Sirtuin Family Histone Deacetylases in Acute Myeloid Leukemia – A Promising Road Ahead

A peer-reviewed article of this preprint also exists.

Submitted:

16 February 2025

Posted:

17 February 2025

You are already at the latest version

Abstract
Acute myeloid leukemia (AML) corresponds to a heterogeneous group of clonal hematopoietic diseases, which are characterized by uncontrolled proliferation of malignant transformed myeloid precursors and their inability to differentiate into mature blood cells. The prognosis of AML depends on many variables, including the genetic features of the disease. Treatment outcomes, despite the introduction of new targeted therapies, are still unsatisfactory. Recently, there have been an increasing number of reports on enzymatic proteins of the sirtuin family and their potential importance in cancer in general. Sirtuins are a group of 7 (SIRT1-7) NAD+-dependent histone deacetylases with pleiotropic effects on metabolism, aging processes, and cell survival. They are not only responsible for post-translational modification of histones but also play various biochemical functions and interact with other proteins regulating cell survival, such as p53. Thus, their role in key mechanisms of tumorigenesis makes them a worthwhile topic in AML. Different sirtuins have been shown to act oppositely depending on the biological context, the mechanism of which requires further exploration. This review provides a comprehensive description of the significance and role of sirtuins in AML in the light of the current state of knowledge. It focuses in particular on molecular mechanisms regulated by sirtuins and signaling pathways involved in leukemogenesis, as well as clinical aspects and potential therapeutic targets in AML.
Keywords: 
acute myeloid leukemia
;  
sirtuins
;  
SIRTs
;  
epigenetics
;  
targeted treatment
Subject: 
Medicine and Pharmacology  -   Hematology

Introduction

In acute myeloid leukemia (AML) genetic and epigenetic abnormalities occur in more than 97% of patients and accumulate in pre-leukemic hematopoietic stem cells (HSCs). Their multiplicity finally results in the development of abnormal primitive hematopoietic precursor cells called leukemic stem cells (LSCs) and following pathological blasts, leading to the evident leukemic transformation [1,2]. Leukemogenesis is a gradual and heterogeneous process characterized by hyperproliferation of aberrant blasts and blockade of their differentiation into mature myeloid cells [3]. Eventually, this uncontrolled clonal proliferation of non-differentiated myeloid progenitor cells results in the inhibition of normal hematopoiesis in the bone marrow [4].
The mechanism of leukemogenesis includes abnormalities in regulators of apoptosis, tyrosine kinases, and transcription factors such as TP53 deletions, chromosomal aberrations or single nucleotide polymorphisms (SNP) of genes participating in key signaling pathways for cellular homeostasis. Moreover, changes in epigenetic modifiers are also critical [5]. This complex pathogenicity results in unsatisfactory AML treatment outcomes, which is related to the inability to eradicate LSCs with conventional chemotherapy and frequent relapses as a consequence [6]. Potential mechanisms of drug resistance in LSCs include quiescence, that is going into a latent state, and exploiting cell cycle regulation to their advantage. In addition, LSCs show lower levels of reactive oxygen species (ROS) and higher expression of autophagy-related genes, which increases toxic molecules elimination. Furthermore, LSCs are rich in altered epigenetic mechanisms, including hypermethylation and histone modification [7]. Finally, they are able to infiltrate HSC niche, utilize the bone marrow microenvironment for survival and create a reservoir for residual disease [8]. In addition, there is evidence that the survival of LSCs also depends on oxidative phosphorylation and its critical regulatory metabolite nicotinamide adenine dinucleotide (NAD+) [9]. This implies that targeting AML resistance and eradicating measurable residual disease (MRD) requires a complex therapeutic approach, including the role of epigenetics and cellular metabolism.
Sirtuins (SIRTs) are histone deacetylases, a class of NAD+-dependent proteins which regulate different cell pathways such as oxidative stress, DNA repair, transcriptional regulation, inflammation, and cellular senescence [10]. Thus, their impact on physiological and/or pathological processes is crucial. SIRTs play also a specific and important role in cancer biology [11]. They can both promote and inhibit tumorigenesis, depending on various genetic contexts, tumor type, and stage by acting as double-edged weapon [12,13]. Moreover, they affect regulated cell death (RCD), particularly apoptosis, whose dysregulation facilitates development and progression of AML by permitting continued survival of cells with activated oncogenes [2].
More recently, SIRTs were discovered to play an important role in the maintenance and differentiation of LSCs, therefore representing a promising area of scientific interest and a potential therapeutic target in hematologic oncology [14,15]. Their role in the pathogenesis, chemoresistance, and prognosis in solid tumors has been widely discussed [16,17,18,19,20,21]. However, there are still no conclusive data evaluating the effect of SIRTs on hematologic malignancies. This knowledge could help to develop new classes of personalized therapies in AML, where, despite novel targeted therapies, treatment resistance remains a challenge. Hence, new therapeutic concepts and tailored approaches to AML treatment are needed in daily clinical practice. We believe it is critical to thoroughly understand the role of SIRTs and their mechanisms of action in AML before effective strategies can be designed.
This review aims to provide a comprehensive overview of SIRTs in AML and in particular, to examine clinically relevant current and future aspects related to SIRTs, highlighting the molecular background.

The Sirtuin Family

Since the discovery of the silent information regulator 2 (Sir2) protein in Saccharomyces cerevisiae in 1979’ [15], seven SIRT homologs (SIRT1-7) with different substrate preferences, enzymatic activities, cellular localization, and targets have been described [22].
One of the main biochemical mechanisms by which SIRTs exert their biological function is deacetylation [23]. To better understand the nature of this process, it is necessary to look at genomics. The human genome contains approximately 25,000 protein-coding genes, while more than 90,000 proteins have been identified. Three mechanisms are responsible for the diversity of these structures: alternative splicing of precursor mRNA, single aminoacid polymorphisms, and post-translational modifications (PTM) [24]. One of principal subtypes of PTMs is acylation, being a process of attachment of an acyl group, in particular an acetyl group (acetylation), to a protein [25]. On the other hand, deacetylation constitutes the dissociation of the acetyl group. Both acetylation and deacetylation are responsible for numerous functions, including an epigenetic mechanism of gene expression control [26].
A specific form of PTM related to the control of gene expression is histone modification. In the 1960s, it was shown that acetylation of the internal lysine residue of a histone causes neutralization of the positive lysine charge, thereby relaxing the chromatin conformation and increasing transcriptional activity [27,28]. Deacetylation, on the other hand, involves hydrolysis of an acetyl group from an acetyl-lysine residue and is carried out by deacetylases, thus leading to chromatin condensation and gene expression silencing [24,29]. Histone deacetylases (HDACs) are important and well-described enzymes [30]. There are 18 known representatives of HDACs divided into four classes. Zinc-dependent classes include classes: I (HDACs 1, 2, 3, and 8), IIa (HDACs 4, 5, 7, and 9), IIb (HDACs 6 and 10) and IV (HDAC 11). SIRT1-7 constitute NAD-dependent class III HDACs (Figure 1) [31,32,33].

Classification of Sirtuins

SIRTs are divided into four classes based on the conserved catalytic core domain. SIRTs 1-3 belong to class I, SIRT4 and SIRT5 to class II and III respectively, and class IV is represented by SIRTs 6-7. These proteins have also different intracellular localization. SIRT1, 6, and 7 are mainly located in the cell nucleus, SIRTs 3-5 are mitochondrial, whereas SIRT2 is cytosolic and can move into the nucleus during mitosis [34,35]. SIRTs are not only histone deacetylases. They can target proteins regulating cell apoptosis and proliferation and modulate the activity of both suppressor proteins (p53) and protooncogenes (cellular myelocytomatosis oncogene; c-MYC), as well as enzymes involved in metabolic processes (carbamoyl phosphate synthetase 1; CPS1, glutamate dehydrogenase; GDH) [36]. SIRTs 1-3 mainly exhibit strong deacetylating properties, while the other members of the SIRT family are weaker deacetylases, but present additional catalytic functions, like demalonylation, deglutarylation, and desuccinylation. Although SIRTs are best known for their deacetylating activity, some of them have unique features; for instance, SIRT4 acts rather as an adenosine diphosphate (ADP) ribosyltransferase, while SIRT6 also demonstrates ADP-ribosylation capacity, through which it regulates the poly (ADP-ribose) polymerase 1 (PARP1) protein [35]. Different SIRTs were also shown to act oppositely at a given point of capture, as well as depending on the biological context, especially concerning oncogenesis, the mechanism of which remains poorly understood [37]. Indeed, the biology and microenvironment of each tumor differ. Therefore, the description of SIRTs’ action in AML requires special attention and is certainly an interesting topic for exploration.

Overview of the Role of the Sirtuin Family in AML

Sirtuin 1

SIRT1 is the oldest known and best-described human SIRT. Its role in the context of cancerogenesis and its impact on pathways controlling apoptosis and proliferation are widely discussed. This protein has been considered oncogenic since its deacetylating effect on p53 with consequent silencing of its function was described, for example in lung cancer [38,39]. However, in subsequent years, the tumor-suppressive properties of SIRT1 were demonstrated, depending on the type of neoplasm [40]. To date, several potential mechanisms through which SIRT1 may influence the development and course of AML have been described.
The role of SIRT1 in AML may be clearly associated with early stages of the disease. LSCs are thought to be precursors of leukemic blasts and are considered the most possible source of relapse [41]. They are rich in CD34+CD38- subset and it was proven that SIRT1 expression is increased in these cells. It does not explain their effect on leukemogenesis, however, sheds light on their potential involvement in the formation or survival of LCSs [42]. SIRT1 is upregulated in cells derived from AML patients classified into the intermediate- or high-risk group compared to the low-risk group, according to the National Cancer Center Network (NCCN) classification [41,42]. Higher expression of SIRT1 was also found in samples obtained from AML patients with an internal tandem duplication in the FMS-like tyrosine kinase 3 gene (FLT3-ITD) [42,44], which is one of the most common AML subtypes (approximately 25% of all cases) and is connected with an increased risk of relapse [45,46]. SIRT1 overexpression is related to c-Myc network, which reduces SIRT1 ubiquitination and enhances its stability [42]. Moreover, Li et al. found that SIRT1 expression correlates with ubiquitin-specific peptidase 22 (USP22) expression and, through the c-Myc/USP22/SIRT1 pathway, reduces p53 activity and thereby promotes LSCs survival [42]. Elevated levels of SIRT1 were described not only in LSCs but also in blasts derived from AML patients compared to healthy controls [47]. A study by Li-Cheng et al. demonstrated that both gene and protein expression levels of SIRT1 and peroxisome proliferator–activated receptor gamma coactivator (PGC)-1 alpha were higher in AML cells resistant to cytosine arabinoside (AraC) than in primary AML samples [48]. Interestingly, Tian et al. described a negative correlation of SIRT1 gene expression with interferon-regulatory family 9 (IRF9), a protein that can inhibit SIRT1 and thus promote p53 activation [49]. Yet, another important aspect is the potential of epigenetic regulation of gene expression by SIRT1. Chen et al. demonstrated its role in regulating chromatin status in histone-lysine N-methyltransferase 2A (KMT2A) mutated leukemias in which SIRT1, acting as a disruptor of telomeric silencing 1-like (DOT1L) antagonist, can induce gene silencing [50].
Recently, another pathway related to SIRT1, and associated with the forkhead box protein 1 (FOXP1) has been described. The FOXP1 regulator affects the survival of mouse hematopoietic stem cells by suppressing oxidative stress. It has also been shown to affect the growth of AML cells. SIRT1, on the other hand, serves as a sensor of oxidative stress in AML cells. Induction of FOXP1 overexpression increases SIRT1 expression by enhancing SIRT1 protein stability. Consequently, this contributes to resistance to chemotherapy of AML cells [51]. SIRT1 effects on forkhead box protein O1 (FOXO1), signal transducer and activator of transcription 5 (STAT5) -related pathways, and tyrosine kinases like BCR-ABL, promoting leukemogenesis in chronic myeloid leukemia (CML), have also been described [52,53].
It has been shown that the expression and activity of SIRTs can also be influenced by micro RNAs (miRNAs, miRs). miRNAs are short, single-stranded, non-coding RNAs consisting of ~22 nucleotides. By cleavage of complementary mRNAs or their destabilization, they are involved in the post-transcriptional regulation of gene expression, including SIRT genes [54]. For example, it has been proven that miR-9 directly binds to SIRT1 mRNA 3' and silences its translation process. In AML, Zhou et al. showed that patients with the t(8;21) translocation, involving RUNX1-RUNX1T1 gene fusion, have lower miR-9 expression and higher SIRT1 expression [55].
In conclusion, numerous reports indicate an oncogenic effect of SIRT1 in hematological malignancies including AML. By affecting p53 protein and c-Myc-related signaling pathways, it indirectly inhibits apoptosis, promotes maintenance of LSCs, and leads to survival of AML blasts.

Sirtuin 2

SIRT2 is the second representative of the SIRT family. It is known as a cytoplasmic SIRT but has the ability to enter the nucleus during mitosis, where it affects chromatin condensation through interaction with histone H4 Lys 16 [56]. SIRT2 is highly expressed mainly in the cytoplasm of neurons and oligodendrocytes in the brain, and thus is considered to be involved in neurological disorders [57]. SIRT2 has pleiotropic activity in tumorigenesis and can act as a tumor promoter or suppressor depending on factors like microenvironment or metabolic requirements of particular cells [58,59]. SIRT2 might also impact tumors indirectly by affecting immunologic processes through T-cell metabolism regulation [60]. Published data showed that SIRT2 inhibits not only the humoral response, but also macrophages, myeloid-derived cells, and tumor-associated neutrophils in tumor tissues [59]. Interestingly, it can increase lactate dehydrogenase (LDH) activity through its deacetylation, which affects lactic acid accumulation and promotes tumor cell proliferation [61]. There is data that inhibition of SIRT2 can induce apoptosis and autophagy in leukemic cell lines including human T-cell lymphotropic virus type 1 (HTLV-1) transformed T-cells [62]. These findings indicate the role of SIRT2 in the pathophysiology of AML.
Both SIRT2 gene and protein expression was found to be elevated in AML cells comparing to normal tissues or CD34+ cells from healthy individuals [59,63]. Moreover, Deng et al. showed its significantly higher expression in bone marrow samples from patients with high- or intermediate-risk AML than low-risk AML according to the NCCN. High SIRT2 expression was associated with shorter overall survival (OS) and event-free survival (EFS). SIRT2 is presumed to be related to genes of the mitogen-activated protein kinase (MAPK) and vascular endothelial growth factor (VEGF) signaling pathways, the up-regulation of which correlated with SIRT2 expression [64].
Another mechanism of SIRT2 action has been noted in KMT2A mutated AML. The MLL1 protein, encoded by the KMT2A gene, is a methyltransferase that regulates hematopoiesis. This process is mediated by modification of histones in the promoters of target genes. The presence of an abnormal form of the protein leads to neoplastic transformation of hematopoietic cells [65,66]. Hao et al. demonstrated that SIRT2 deacetylase acts as an upregulator for poor prognostic KMT2A-ENL fusion, and loss of SIRT2 increases the chemosensitivity of AML cells bearing this rearrangement [67].
Moreover, the upregulation of SIRT2 mRNA and protein expression in bone marrow samples was observed in patients with relapsed AML as compared to the newly diagnosed population. In addition, SIRT2 inhibition resulted in decreased expression of the multidrug resistance-associated protein 1 (MRP1), which is considered to be a chemotherapy resistance factor in leukemic cells. A positive correlation between SIRT2 expression, extracellular signal-regulated kinase 1 and 2 (ERK1, ERK2), and the anti-apoptotic B-cell lymphoma 2 protein (BCL-2) was also observed. On the other hand, SIRT2 expression correlated negatively with wild-type p53 levels. These results indicate that the ERK1/2 signaling pathway is related to SIRT2 and this interaction may affect multidrug resistance to chemotherapy, as well as modulate apoptosis by regulating both pro- and anti-apoptotic proteins [68].
SIRTs make their mark, as already stated, not only by modifying histones or affecting p53. The mammalian target of rapamycin (mTOR) is a phosphorylase that can stimulate tumor growth by acting on proteins that control cell division and proliferation. It is part of the phosphoinositide-3-kinase/protein kinase B/mTOR (PI3K/AKT/mTOR) signaling pathway. Due to its importance in tumourigenesis, inhibition of this pathway is used for tumor suppression [69]. Luo et al. have recently demonstrated that PI3K/mTOR inhibitor impacted SIRT2-dependent pathways. Moreover, they showed that inclusion of SIRT2 inhibitor had a synergistic suppressing effect on tumor growth and increased survival in a murine model. An increase in wild-type p53 expression was observed, when both PI3K/mTOR and SIRT2 inhibitors were used [70]. Furthermore, Dan et al. assessed the AKT/glycogen synthase kinase-3 beta (GSK3ß)/ß-catenin signaling pathway in AML for the effects of nicotinamide phosphoribosyltransferase (NAMPT) and SIRT2, which showed high expression in blasts. The authors demonstrated that NAMPT and SIRT2 affect the survival and proliferation of blastic cells potentially through inhibition of the mentioned signaling pathway [63]. In another study, the researchers showed that NAMPT and SIRT2 are involved in leukemic transformation through activation of GSK3ß, leading to accumulation of the ß-catenin oncogene in the cell nucleus [71].
Abnormal proliferation, being as aggressive as that observed in acute leukemia, requires complex anabolic processes. These are mediated, inter alia, by the pentose-phosphate pathway, the oxidative branch of which is glucose-6-phosphate dehydrogenase (G6PD). It plays an important role in AML cell proliferation, and its increased activity and downregulated acetylation were proved in AML blasts compared to normal control. SIRT2, by deacetylating G6PD, promotes NADPH production, which drives AML clone proliferation and development [72].
Considering natural agents that have the potential to modulate SIRTs, Russo et al. investigated the effect of flavonoids on monocytic leukemia THP-1 cell line. Naringenin and hesperetin decreased SIRT2 gene expression and thus TP53 deacetylation while modulating the expression of the regulatory proteins p21 and cyclin E1. In this study, flavonoids exerted an antiproliferative effect on leukemic cells by potentially acting on a signaling pathway of which SIRT2 is an essential point [73].
Apart from the mechanisms affecting blast proliferation and survival, clinical management of side effects and toxicity of AML treatment are other important aspects. Induction of remission in acute leukemia, contributed by anthracycline therapy, certainly has a strong toxic effect on the myocardium. Zhao et al. demonstrated that miRNA-140-5p exacerbates this toxicity by increasing oxidative stress through nuclear factor erythroid 2-related factor 2 (NRF2) and SIRT2 targeting. Blocking the miR-140-5p/SIRT2 axis may facilitate treatment of cardiotoxicity during anthracycline chemotherapy [74]. miR-145 is another miRNA, whose effect on SIRT2 in AML may be worth further investigation. Its expression positively correlates with proapoptotic genes, suggesting its potential role in the induction of apoptosis in AML. SIRT2 has appeared to demonstrate significantly negative correlation with miR-145, and this observation may imply that SIRT2 exhibits pro-leukemic activity [75].

Sirtuin 3

SIRT3 is a mitochondrial SIRT, involved in the metabolism and maintenance of mitochondrial homeostasis by regulating acetylation of other proteins. Research shows that SIRT3 influences aging processes. Its association with longevity, and delay in degeneration of neurons or the macula, has been widely described [76]. Additionally, SIRT3 plays a role in both oncogenesis and tumor-suppressor processes [76,77]. In the pathway with phosphatase and tensin homologue deleted on chromosome 10 (PTEN) and mouse double minute 2 homolog (MDM2), it can indirectly inhibit p53 degradation. In consequence, glycolysis in wild-type TP53 cancer cells is inhibited, which leads to tumor suppression [78]. Furthermore, SIRT3 can deacetylate and simultaneously deactivate cyclophilin D and lead to inhibition of glycolysis in breast cancer cells [79]. On the other hand, it can enhance the activity of isocitrate dehydrogenase 2 (IDH2), resulting in oncogenesis stimulation, especially in hematological malignancies [80].
SIRT3 has been confirmed to demonstrate a promoting effect on human LSCs by regulating oxidation of fatty acids required for the production of adenosine triphosphate (ATP). O’Brien et al. demonstrated that SIRT3 inhibition reduces fatty acid oxidation activity and substrate availability for the tricarboxylic acid cycle, thereby affecting oxidative phosphorylation, decreasing ATP production, and leading to LSC death [81]. Furthermore, it has been shown that disruption of cholesterol homeostasis sensitizes LSCs to SIRT3 inhibitors and enhances their apoptosis. Interestingly, inhibition of SIRT3 sensitizes LSCs to venetoclax, which acts as a specific inhibitor of BCL-2 protein [82]. In addition, SIRT3 was shown to inhibit chemotherapy-induced mitochondrial ROS production and increase oxidative phosphorylation in AraC-treated and untreated AML cells. Inhibition of SIRT3 led to blast destruction synergistic with Ara-C both in vitro and in mouse models [83]. The above mechanisms indicate the AML-promoting activity of SIRT3 as well as its impact on chemoresistance, both to classical chemotherapy and to targeted drug therapy.
Another mechanism, affected by SIRT3 in AML, is a specific type of post-translational modification of proteins, called sumoylation. This is a covalent attachment of small ubiquitin-like modifier (SUMO) proteins to the target protein [84]. Dysregulation of SIRT3 sumoylation may enhance AML blast chemoresistance. Desumoylation of SIRT3 increases SIRT3 activity and inhibits the hairy and enhancer of split-1 (HES1) transcription factor, being a part of the Notch1 signaling pathway. As a result, fatty acid oxidation increases, which enhances resistance to chemotherapy. In contrast, inhibition of desumoylation or overexpression of HES1 acts synergistically with AraC in eliminating leukemic blasts in vitro and in mouse models [85]. Jiao MA et al. also demonstrated the importance of SIRT3 sumoylation in AML cell survival. They pointed out that SIRT3 desumoylation decreases generation of ROS and alters mitochondrial metabolism, which may consequently contribute to AML resistance to cytostatic agents [86]. Other studies reveal that downregulation of SIRT3 sensitizes AML blasts to conventional chemotherapy [83].
However, in our study, SIRT3 appeared to be down-regulated in patients with secondary AML, whose prognosis is generally unfavorable [87]. Similarly, some reports demonstrate relatively low expression of SIRT3 in AML, depending on the disease subtype [88]. This may indicate a bidirectional action of this type of SIRT in oncogenesis, therefore, these mechanisms certainly require further research.

Sirtuin 4

SIRT4 is the second representative of the SIRT family that acts mainly in mitochondria [89]. SIRT4 is known to act as both ADP-ribosyl-transferase and lysine deacetylase and plays a role in regulating metabolism, lipid homeostasis, insulin secretion, and cell cycle [90]. It is particularly prevalent in white blood cells and adult thymus [91]. SIRT4 is considered a tumor suppressor gene. Its overexpression was shown to inhibit glutamine metabolism and thus the growth of Burkitt’s lymphoma cells [92,93]. As compared to healthy tissues, decreased mRNA levels of SIRT4 were observed in many neoplasms, including breast, stomach, thyroid, bladder, colon, and ovary cancers [94]. Reduced SIRT4 expression was also associated with advanced pathological grading and poor survival in many types of solid tumors [90,95]. Other studies, however, provide evidence for esophageal cancer-promoting SIRT4 activity [96].
There is little data regarding SIRT4’s impact on AML. Bradbury et al. performed a study characterizing expression of all 18 histone deacetylases in AML blasts compared to peripheral blood mononuclear cells (PBMC) as well as CD34+ progenitors derived from the umbilical cord or granulocyte colony-stimulating factor (G-CSF)-stimulated healthy donors. SIRT4, as well as HDAC5, were the only genes consistently underexpressed in leukemic blasts in comparison with PBMC and CD34+ progenitors. What is more, HDACs inhibitors (HDI) induced diverse changes in HDACs genes expression, depending on the inhibitor, its concentration, or cell type. However, only SIRT4 of all the SIRT family showed consistent up-regulation with all inhibitors. It may imply that it demonstrates opposite activity compared to other SIRT members under the conditions of HDI implementation [97].
In our previous studies, we also noted a strong positive correlation between SIRT4 and anti-oncogene wild-type TP53 expression in leukemic cells [98].
There is evidence that SIRT4 might influence the pathogenesis of other hematologic malignancies. Knocking out SIRT4 in mice led to spontaneous development of lymphomas [92]. Moreover, it was found that SIRT4 can inhibit growth of Myc-induced B-cell lymphoma [93]. The presented data highlight the tumor-suppressing effect of SIRT4 in the context of neoplasms originating from blood and bone marrow cells.
On the other hand, some reports reveal an up-regulation and promoting effect of SIRT4 on formation of malignant tumors, including AML. O’Brien et al. showed that SIRT4 knockdown had an inhibitory effect on the viability and colony-forming ability of AML specimens [82]. One source points to overexpression of SIRT4 in AML, but at the same time it questions its direct causative relationship with leukemogenesis. High expression of SIRT4 may be explained by boosted proliferative activity of blasts and thus increased cells’ demand for mitochondrial metabolism, which can lead to SIRT4 up-regulation [99].
The above data, as well as literature describing SIRT4 in oncology generally, demonstrate that SIRT4 is predominantly established as a tumor suppressor [100]. This molecule plays an important role in the damage response of mitochondrial metabolism, which may inhibit tumor initiation [92]. SIRT4 is believed to play a less important role in oncogenesis, and there is little data on this relationship. Yet, as it happens with the entire SIRT family, the mechanisms are ambivalent, and prooncogenic actions of SIRT4 have also been described. Jeong et al. claim that one of explanations for this phenomenon is the fact that cancer cells are able to modulate the stress response in their favor and this ability enables them to grow [101].

Sirtuin 5

SIRT5 is another mitochondrial SIRT [102]. It is a lysine deacetylase, but some data confirm its demalonylase, deglutarylase, and desuccinylase activity [103,104,105]. SIRT5 acts mainly in the intermembrane spaces of mitochondria, and its expression is highest in the heart, brain, liver tissues, and lymphoblasts [106]. It regulates a wide range of metabolic pathways, including those related to energy metabolism and apoptosis [107]. SIRT5 plays an important role in downregulation of oxidative stress and can protect some cancer cells from stress-induced apoptosis [108,109]. It may also increase the expression of BCL-2 and decrease apoptotic bcl-2-like protein 4 (BAX) [110]. These proteins are involved in signaling pathways crucial for cell survival, and common mechanism for cancer cells to avoid apoptosis is upergulation of BCL-2 and loss of BAK. BCL-2 is also a major target for venetoclax-based targeted therapies in hematologic malignancies [111]. These data may suggest SIRT5’s pro-oncogenic activity, possibly leading to tumor maintenance.
SIRT5 is required to make mitochondrial oxidative phosphorylation and other key processes run in AML blasts [112]. Yan D. et al. described the dependence of survival and growth of primary AML cells on SIRT5, being a regulator of energy metabolism. SIRT5 can be efficiently inhibited by the NRD167 molecule, which increases mitochondrial superoxide, reduces oxidative phosphorylation and apoptosis. It was also confirmed that the knockdown of SIRT5 in AML blasts reduced colony formation and inhibited growth in AML cell lines [113]. Such effect was not observed in normal cells, which suggests that SIRT5 knockdown in AML cell lines preferentially targets AML blasts [114].
It is supposed that SIRT modulation could be a therapeutic strategy in AML. Rajabi N. et al. designed a masked tetrazolium-containing molecule showing selective cytotoxicity and enhanced activity against SIRT5-dependent AML cell lines. The mechanism is based on the inclusion of carboxylic acid isosters, which play a role in binding to the active site of the enzyme [115]. Other data confirm dependence of AML cells on SIRT5 but this correlation was not found for CD34+ cells. What is more, SIRT5 knockout mice demonstrated impaired transformation of hematopoietic cells by myeloid oncogenes in vitro, and attenuated leukemogenesis was observed in vivo. [116].
Wang M. et al. proved synergistic activity between administration of venetoclax and inhibition of SIRT5 in AML. Venetoclax-resistant patients had elevated NAD+ metabolism, and the authors hypothesized that knockdown of SIRT5 may increase venetoclax activity via attenuation of NAD+ metabolism. Indeed, this combination leads to numerous processes, like increased production of ROS, decreased ATP generation, and consequently increased apoptosis in AML cells [117].
Some reports indicate that deacetylase and desuccinase activities of SIRT5 can be modulated by resveratrol, a natural polyphenol characterized with antioxidant and anticancer properties [118]. Ozkan T. et al. found that in K562 CML cells resveratrol decreased the SIRT5 level and induced apoptosis, which, hypothetically, may have been mediated by SIRT5-lowering effect [119]. However, there is no data regarding the effect of resveratrol on AML.
Being a key metabolic regulator in AML, SIRT5 is believed to be essential for the survival of LSCs. Knockout of SIRT5 in mouse models leads to rapid apoptosis of AML cells and disease regression. However, some cell lines were resistant to SIRT5 inhibition. These findings were analyzed by Bateman B. et al. and their study revealed that AML samples with nucleophosmin 1 mutations (NPM1mut) showed predominantly SIRT5-independent nature. It has been shown that cells with NPM1mut increased mitochondrial DNA in the cytosol. Proliferation of SIRT5-independent NPM1mut cells results from adaptation to mitochondrial dysfunction. In contrast, SIRT5 depletion in SIRT5-dependent samples showed apoptotic effects on AML cells [120]. This demonstrates the complex nature of AML, which depends on genetic aberrations, including changes that cause mitochondrial damage. On the other hand, it has been observed that glioma cells with IDH1 (R132H) mutations (IDH1mut) exhibit hypersuccinylation leading to increased expression of the antiapoptotic BCL-2. IDH1mut enhance succinylation, shutting down mitochondrial respiration, and thus inducing apoptosis blockade. Overexpression of the SIRT5 desuccinylase results in inhibition of tumor growth in these cases [121,122]. In contrast, SIRT5 action in the IDH1mut AML subgroup still has not been thoroughly described.
Vast majority of data on the effect of SIRT5 on AML point to its leukemogenesis-promoting nature. This observation is not fully supported by the literature concerning solid tumors in general, where its mechanisms are described as either tumor-promoting or -inhibiting, even in the same tumor subtype, depending on the biological context [123]. However, given the heterogeneity of AML, analyses of the effect of SIRT5 on molecular subgroups, such as those with IDH or FLT3 mutations, are still limited.

Sirtuin 6

SIRT6 is a nuclear SIRT, which acts as both a histone deacetylase and ADP-ribosilotransferase [124]. Its presence is mainly observed in skeletal muscles, liver, brain, heart, and thymus [125]. It is also known to regulate processes like DNA repair, metabolism, inflammation, and telomere maintenance [124,126]. SIRT6 is called the longevity gene, as it plays a key role in aging inhibition [127]. However, its ability to repair DNA also makes it widely discussed in the context of oncogenesis. The capacity of SIRT6 to inhibit tumor formation consists in maintaining genome integrity, and downregulation of SIRT6 in ovarian, breast, colon, and liver cancers has been documented [128,129,130,131]. Furthermore, according to the Cancer Cell Line Encyclopedia report, more than one-third of cancer cell lines included in their database contain a deletion of the SIRT6 gene [132]. There are data supporting an anti-oncogenic effect of SIRT6. However, this protein, like other SIRTs, exhibits also negative characteristics; its increased expression has been shown in squamous cell carcinoma and hematological malignancies, including AML [133,134,135,136,137].
Cagnetta A. et al. observed that SIRT6 was overexpressed in AML CD34+ blasts, but underexpressed in normal CD34+ hematopoietic stem cells. They also demonstrated that depletion of SIRT6 in AML cells increases their susceptibility to classical cytotoxic drugs such as daunorubicin and AraC. The authors hypothesize that the DNA repair functions of SIRT6, which are beneficial in the physiological state, work in favor of AML here, and SIRT6 inactivation increases the toxicity of chemotherapy [137]. Furthermore, SIRT6 is also referred to as a guardian of the genome of AML cells, which may be responsible for chemoresistance. An Italian study conducted by Cea M. et al. confirmed high expression of SIRT6 in 200 AML patients, as well as a positive correlation between SIRT6 expression and high chromosome instability, and proved its adverse prognostic value. SIRT6 up-regulation was also observed in AML cell lines characterized mainly by constitutive DNA damage. It is hypothesized that the combination of genotoxic therapies with SIRT6 inhibition may provide a tangible benefit particularly to poor-prognosis AML patients [138]. It was also shown that patients with FLT3-ITD mutation were low expressors of SIRT6. Such correlation was not observed between SIRT6 and NPM1, Wilms tumor (WT1) mutations, or brain and acute leukemia cytoplasmic (BAALC) gene expression. It was further demonstrated that depletion of SIRT6 increased sensitivity to drugs such as idarubicin, AraC, and fludarabine, and confirmed poor EFS and OS in high expressors of SIRT6 [139]. Moreover, Hubner S. et al. reported that high SIRT6 expression had an adverse effect on remission duration in both pediatric and adult AML patients [140].
In another study, Carraway HE et al. investigated DNA hypomethylating agents (HMAs), such as 5-azacytidine and decitabine, both in terms of their effects on reversing DNA methylation and on HDACs actions, including SIRTs. They showed that HMAs increase the enzymatic activity of SIRT6 but have no significant effect on other SIRTs. The authors hypothesized that SIRT6 activation may be an additional HMAs attempt to repair DNA of leukemic cells and restore tumor-suppressing genes. Thus, the authors suggest that combination of HMAs and SIRT6 inhibitors or chemotherapeutics may not be effective due to their opposite mechanisms of action [141].
Zhang Y. et al. investigated the effect of LINC00319, a long non-coding RNA, highly expressed in AML, on AML cells. They found that the molecule is responsible for a mechanism that promotes leukemogenesis by increasing SIRT6 expression. Furthermore, the analysis showed that SIRT6 overexpression suppressed the effect of LINC00319 knockdown on AML cells, promoting their growth [142]. Zhang P. et al., however, performed a study in which they proved that knockout of HDAC8 and SIRT6 sensitizes AML cells to NAMPT inhibitors, suggesting its synergistic effect on leukemic blasts [143]. Shi X. et al. conducted a study on NAMPT and nicotinamide nucleotide adenylyltransferase 1 (NMNAT1) and demonstrated that deletion of NMNAT1 reduced nuclear NAD+, leading to weaker SIRT6 and SIRT7 activity. This resulted in reduced deacetylation and p53 activation, thus leading to sensitization of AML to venetoclax. Deletion of SIRT6 and SIRT7 in AML cells also increased apoptosis; interestingly, this effect was not observed in SIRT1 deletion [144]. Furthermore, Yang X. et al. found that DNA (cytosine-5)-methyltransferase 3A (DNMT3A) mutation, common in AML, resulted in high NAMPT expression. The authors demonstrated that NAMPT inhibition induced cyclin-dependent kinase complex (cyclin-CDK) depolymerization through SIRT6, which resulted in increased mouse survival and decreased leukemic cell infiltration [145].
SIRT6, a molecule that is important in DNA repair and has an anti-oncogenic effect in most cancers, appears to be sneaky in AML and can work in favor of the disease.

Sirtuin 7

The last member of the SIRT family, SIRT7, acts in both the nucleus and nucleolus, playing a role in multiple processes, like transcription and regulation of metabolism, stress response, aging, tumorigenesis, and genome stability [146]. One of its main biological activities is histone 3 on lysine residue 18 (H3K18) deacetylation, and consequently, chromatin packing, which in turn, inhibits transcription [146,147]. Additionally, the desuccinylate ability of SIRT7 has been described, which also alters chromatin and impacts gene expression [148]. In the nucleus, on the other hand, SIRT7 is responsible for stabilizing rDNA heterochromatin, thus influencing the production of ribosomes [149]. In tumorigenesis, SIRT7, unsurprisingly, plays a dualistic role, depending on the biological context. Its crucial genome-stabilizing function counteracts tumor development. Nevertheless, it seems that in cells which are already malignant, SIRT7 can act as either an anti- or pro-oncogenic molecule [150]. Barber MF et. al. demonstrated that high H3K18 deacetylation by SIRT7 enhances the persistence of the malignant phenotype of cancer cells [151,152]. In addition, SIRT7 can attenuate transcription of specific tumor-suppressor genes and has the ability to produce rRNA for metabolic needs of the cancer cell [151,153]. High levels of SIRT7 were associated with aggressive and metastatic prostate and gastric carcinomas [154,155]. Increased expression of SIRT7 has also been described in hepatic, ovarian, breast, and lung cancers but it appears to be a tumor suppressor in head and neck squamous cell carcinoma [156,157,158,159,160].
In most cases, SIRT7 is well known for its tumor-promoting functions. However, in hematologic malignancies, including AML, the protein seems to act differently. Raza U. et al. described the effect of SIRT7 on nuclear respiratory factor 1 (NRF1) in hematopoietic stem cells, which involves inhibition of transcription of ribosomal proteins hereby reducing stress and enabling to maintain a pool of HSCs, which in turn protects the cells from leukemogenesis [161]. Similar conclusions were reached by Wang Y. et al. who noted that SIRT7 promotes HSCs by inhibiting mitochondrial folding stress and mitochondrial NRF1 activity [162]. These data correlate with results obtained by Nowicki M. et al. in their study, which focused on the efficacy of HSCs mobilization prior to autologous transplantation in patients with myeloma and lymphoma. The analysis revealed that upregulation of SIRT7 was noted in patients with high levels of stem cell on day 1 of apheresis. Interestingly, SIRT7 expression was also higher in patients who achieved complete remission before mobilization compared to those who demonstrated partial remission [163]. Kaiser A. et al. showed that SIRT7 expression levels in leukocytes from healthy people decrease in the old-age. As it is generally known, AML incidence tends to grow with age. Similarly, the authors described low SIRT7 expression in patients with AML and CML. What is more, its expression changed with disease activity - it increased with a positive response to treatment, while progression or relapse was associated with a subsequent decrease in the SIRT7 level [164]. The above data indicate that SIRT7 could serve as a potential biomarker in monitoring treatment response in the above diseases, as well as in the prognosis of HSCs harvesting.
A gene expression analysis in AML patients without cytogenetic abnormalities, performed by Metzeler K. et al., showed that low SIRT7 mRNA expression was associated with shorter OS, especially in the FLT3-ITD-mutated subgroup (p=0.011) [165]. Our previous preliminary data revealed a reduction in SIRT7 mRNA levels in patients with FLT3-ITDmut (p=0.07) [87]. These results are consistent with data published by Kaiser A. et al., who described higher SIRT7 expression in FLT3-ITD-negative patients compared to FLT3-ITDmut patients [164]. Furthermore, some key proteins in leukemogenesis, like p53 and NPM1, are substrates for SIRT7 [166,167]. Ianni A. et al. demonstrated that SIRT7 can mediate NPM1 deacetylation, leading in consequence to p53 stabilization under UV-induced genotoxic stress in the skin [168]. On the other hand, Shi H. et al. point to a pathway consisting of NMNAT1-SIRT7-p53 that mediates AML cell survival [144]. Regulatory properties of SIRT7 on p53 levels and function are also described in other studies but their results are not conclusive [167,169,170,171]. Interestingly, both SIRT7 and TP53 are located on chromosome 17, which is affected by frequent aberrations in acute leukemias [88]. These mechanisms need to be further explored, also in the AML context.
The summarized SIRTs role in AML and their interactions are listed in Table 1.

Therapeutic Applications/Implications

HDAC inhibitors have been evaluated in clinical trials for many hematological malignancies. Vorinostat and belinostat have recently been approved in cutaneous T cell lymphoma (CTCL) and peripheral T cell lymphoma (PTCL), respectively [172,173]. In AML numerous trials investigating combinations of standard chemotherapy with HDACs inhibitors, including vorinostat (NCT00656617), belinostat (NCT00878722), pabinostat (NCT01451268), entinostat (NCT00313586), romidepsin (NCT00062075) have been carried out. However, no effective molecule has yet been identified [174]. There are some hopes associated with chidamide, whose synergistic effect with cladribine has been confirmed on AML cell lines (NCT05330364), or the combination of belinostat with pevonedistat, a selective NEDD8 inhibitor involved in several mechanisms, including neddylation, which influences cell death (NCT03772925) [2,175,176,177]. It is worth noting that most of the mentioned molecules inhibit HDACs of classes: I, II and IV, and therefore do not directly affect SIRTs. There are also several selective SIRT inhibitors, such as Tenovin-6, which are subject to preclinical studies but have not been applied in AML, yet [178]. The mechanisms of action of SIRTs and, consequently, their modulators, are still unclear so taming these molecules for therapeutic purposes poses a challenge and requires further efforts and research. Selected SIRT modulators and they mechanisms of action are listed in Table 2.

Conclusions

Our knowledge of SIRT regulation mechanisms is constantly expanding, and it may result in new diagnostic and therapeutic possibilities. Despite promising results of preclinical studies, we still have not identified effective selective SIRT modulators in clinical trials. The potential reason might be the dual nature of SIRTs in the context of cancer, which makes development of anti-cancer drugs challenging. Nevertheless, a better understanding of the role of SIRTs in AML, and particularly in the regulation of p53, may translate into a selection of novel targets for more personalized therapeutic approach. Undoubtedly, SIRTs play a complex role in AML and, especially for certain AML subtypes, interference in these pathogenetic pathways may represent a treatment strategy.

Author Contributions

Conceptualization, P.S. and A.W. (Agnieszka Wierzbowska).; methodology, P.S. and A.W. (Agnieszka Wierzbowska); formal analysis, A.W. (Aneta Wiśnik) and I.Z.; writing—original draft preparation, P.S. and K.K.; writing—review and editing, D.J. and M.C.; visualization, P.S. and K.K.; supervision, A.P. and A.W. (Agnieszka Wierzbowska). All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

We thank Dorota Wawrzyinak from the Medical University of Lodz, Poland, for language assistance.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Velten, L.; Story, B.A.; Hernández-Malmierca, P.; Raffel, S.; Leonce, D.R.; Milbank, J.; Paulsen, M.; Demir, A.; Szu-Tu, C.; Frömel, R.; Lutz, C.; Nowak, D.; Jann, J.C.; Pabst, C.; Boch, T.; Hofmann, W.K.; Müller-Tidow, C.; Trumpp, A.; Haas, S.; Steinmetz, L.M. Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics. Nat Commun. 2021, 12, 1366. [Google Scholar] [CrossRef]
  2. Stelmach, P.; Trumpp, A. Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica. 2023, 108, 353–366. [Google Scholar] [CrossRef] [PubMed]
  3. Huang, F.T.; Sun, J.; Zhang, L.; He, X.; Zhu, Y.H.; Dong, H.J.; Wang, H.Y.; Zhu, L.; Zou, J.Y.; Huang, J.W.; Li, L. Role of SIRT1 in hematologic malignancies. J Zhejiang Univ Sci B. 2019, 20, 391–398. [Google Scholar] [CrossRef] [PubMed]
  4. Batsivari, A.; Grey, W.; Bonnet, D. Understanding of the crosstalk between normal residual hematopoietic stem cells and the leukemic niche in acute myeloid leukemia. Exp Hematol. 2021, 95, 23–30. [Google Scholar] [CrossRef]
  5. Chen, Y.; Li, J.; Xu, L.; Găman, M.A.; Zou, Z. The genesis and evolution of acute myeloid leukemia stem cells in the microenvironment: From biology to therapeutic targeting. Cell Death Discov. 2022, 8, 397. [Google Scholar] [CrossRef]
  6. Shlush, L.I.; Mitchell, A.; Heisler, L.; Abelson, S.; Ng, S.W.K.; Trotman-Grant, A.; Medeiros, J.J.F.; Rao-Bhatia, A.; Jaciw-Zurakowsky, I.; Marke, R.; McLeod, J.L.; Doedens, M.; Bader, G.; Voisin, V.; Xu, C.; McPherson, J.D.; Hudson, T.J.; Wang, J.C.Y.; Minden, M.D.; Dick, J.E. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature. 2017, 547, 104–108. [Google Scholar] [CrossRef] [PubMed]
  7. Khaldoyanidi, S.K.; Hindoyan, A.; Stein, A.; Subklewe, M. Leukemic stem cells as a target for eliminating acute myeloid leukemia: Gaps in translational research. Crit Rev Oncol Hematol. 2022, 175, 103710. [Google Scholar] [CrossRef]
  8. Kumar, B.; Garcia, M.; Weng, L.; Jung, X.; Murakami, J.L.; Hu, X.; McDonald, T.; Lin, A.; Kumar, A.R.; DiGiusto, D.L.; Stein, A.S.; Pullarkat, V.A.; Hui, S.K.; Carlesso, N.; Kuo, Y.H.; Bhatia, R.; Marcucci, G.; Chen, C.C. Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion. Leukemia. 2018, 32, 575–587. [Google Scholar] [CrossRef]
  9. Lagadinou, E.D.; Sach, A.; Callahan, K.; Rossi, R.M.; Neering, S.J.; Minhajuddin, M.; Ashton, J.M.; Pei, S.; Grose, V.; O'Dwyer, K.M.; Liesveld, J.L.; Brookes, P.S.; Becker, M.W.; Jordan, C.T. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013, 12, 329–41. [Google Scholar] [CrossRef]
  10. Carafa, V.; Altucci, L.; Nebbioso, A. Dual Tumor Suppressor and Tumor Promoter Action of Sirtuins in Determining Malignant Phenotype. Front Pharmacol. 2019, 10, 38. [Google Scholar] [CrossRef]
  11. Lin, Z.; Fang, D. The Roles of SIRT1 in Cancer. Genes Cancer. 2013, 4, 97–104. [Google Scholar] [CrossRef]
  12. Chalkiadaki, A.; Guarente, L. The multifaceted functions of sirtuins in cancer. Nat Rev Cancer. 2015, 15, 608–24. [Google Scholar] [CrossRef] [PubMed]
  13. Mei, Z.; Zhang, X.; Yi, J.; Huang, J.; He, J.; Tao, Y. Sirtuins in metabolism; DNA repair and cancer. J Exp Clin Cancer Res. 2016, 35, 182. [Google Scholar] [CrossRef]
  14. Dong, Z.; Cui, H. Function of Sirtuins in Cancer Stem Cells. Int J Stem Cell Res Ther. 2016, 3, 024. [Google Scholar] [CrossRef]
  15. Wu, Q.J.; Zhang, T.N.; Chen, H.H.; Yu, X.F.; Lv, J.L.; Liu, Y.Y.; Liu, Y.S.; Zheng, G.; Zhao, J.Q.; Wei, Y.F.; Guo, J.Y.; Liu, F.H.; Chang, Q.; Zhang, Y.X.; Liu, C.G.; Zhao, Y.H. The sirtuin family in health and disease. Signal Transduct Target Ther. 2022, 7, 402. [Google Scholar] [CrossRef] [PubMed]
  16. Haq, M.F.U.; Hussain, M.Z.; Mahjabeen, I.; Akram, Z.; Saeed, N.; Shafique, R.; Abbasi, S.F.; Kayani, M.A. Oncometabolic role of mitochondrial sirtuins in glioma patients. PLoS One. 2023, 18, e0281840. [Google Scholar] [CrossRef] [PubMed]
  17. Li, J.; Zhan, H.; Ren, Y.; Feng, M.; Wang, Q.; Jiao, Q.; Wang, Y.; Liu, X.; Zhang, S.; Du, L.; Wang, Y.; Wang, C. Sirtuin 4 activates autophagy and inhibits tumorigenesis by upregulating the p53 signaling pathway. Cell Death Differ. 2023, 30, 313–326. [Google Scholar] [CrossRef]
  18. Shi, Q.; Liu, T.; Zhang, X.; Geng, J.; He, X.; Nu, M.; Pang, D. Decreased sirtuin 4 expression is associated with poor prognosis in patients with invasive breast cancer. Oncol Lett. 2016, 12, 2606–2612. [Google Scholar] [CrossRef]
  19. Tang, X.; Li, Y.; Liu, L.; Guo, R.; Zhang, P.; Zhang, Y.; Zhang, Y.; Zhao, J.; Su, J.; Sun, L.; Liu, Y. Sirtuin 3 induces apoptosis and necroptosis by regulating mutant p53 expression in small-cell lung cancer. Oncol Rep. 2020, 43, 591–600. [Google Scholar] [CrossRef]
  20. Wu, X.; Wang, S.; Zhao, X.; Lai, S.; Yuan, Z.; Zhan, Y.; Ni, K.; Liu, Z.; Liu, L.; Xin, R.; Zhou, X.; Yin, X.; Liu, X.; Zhang, X.; Cui, W.; Zhang, C. Clinicopathological and prognostic value of SIRT6 in patients with solid tumors: a meta-analysis and TCGA data review. Cancer Cell Int. 2022, 22, 84. [Google Scholar] [CrossRef]
  21. Goes, J.V.C.; Carvalho, L.G.; de Oliveira, R.T.G.; Melo, M.M.L.; Novaes, L.A.C.; Moreno, D.A.; Gonçalves, P.G.; Montefusco-Pereira, C.V.; Pinheiro, R.F.; Ribeiro Junior, H.L. Role of Sirtuins in the Pathobiology of Onco-Hematological Diseases: A PROSPERO-Registered Study and In Silico Analysis. Cancers. 2022, 14, 4611. [Google Scholar] [CrossRef] [PubMed]
  22. Costa-Machado, L.F.; Fernandez-Marcos, P.J. The sirtuin family in cancer. Cell Cycle. 2019, 18, 2164–2196. [Google Scholar] [CrossRef]
  23. Sauve, A.A. Sirtuin chemical mechanisms. Biochim Biophys Acta. 2010, 1804, 1591–603. [Google Scholar] [CrossRef]
  24. Teixeira, C.S.S.; Cerqueira, N.M.F.S.A.; Gomes, P.; Sousa, S.F. A Molecular Perspective on Sirtuin Activity. Int J Mol Sci. 2020, 21, 8609. [Google Scholar] [CrossRef]
  25. Towler, D.A.; Gordon, J.I.; Adams, S.P.; Glaser, L. The biology and enzymology of eukaryotic protein acylation. Annu Rev Biochem. 1988, 57, 69–99. [Google Scholar] [CrossRef] [PubMed]
  26. Mai, A.; Massa, S.; Rotili, D.; Cerbara, I.; Valente, S.; Pezzi, R.; Simeoni, S.; Ragno, R. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev. 2005, 25, 261–309. [Google Scholar] [CrossRef]
  27. Allfrey, V.G.; Faulkner, R.; Mirsky, A.E. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci U S A. 1964, 51, 786–94. [Google Scholar] [CrossRef] [PubMed]
  28. Kim, S.C.; Sprung, R.; Chen, Y.; Xu, Y.; Ball, H.; Pei, J.; Cheng, T.; Kho, Y.; Xiao, H.; Xiao, L.; Grishin, N.V.; White, M.; Yang, X.J.; Zhao, Y. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell. 2006, 23, 607–18. [Google Scholar] [CrossRef]
  29. Brachmann, C.B.; Sherman, J.M.; Devine, S.E.; Cameron, E.E.; Pillus, L.; Boeke, J.D. The SIR2 gene family; conserved from bacteria to humans; functions in silencing; cell cycle progression; and chromosome stability. Genes Dev. 1995, 9, 2888–902. [Google Scholar] [CrossRef]
  30. Barneda-Zahonero, B.; Parra, M. Histone deacetylases and cancer. Mol Oncol. 2012, 6, 579–89. [Google Scholar] [CrossRef]
  31. Rosato, R.R.; Grant, S. Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets. 2005, 9, 809–24. [Google Scholar] [CrossRef] [PubMed]
  32. Sawas, A.; Radeski, D.; O'Connor, O.A. Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review. Ther Adv Hematol. 2015, 6, 202–8. [Google Scholar] [CrossRef] [PubMed]
  33. Bose, P.; Dai, Y.; Grant, S. Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther. 2014, 143, 323–36. [Google Scholar] [CrossRef]
  34. Zhao, E.; Hou, J.; Ke, X.; Abbas, M.N.; Kausar, S.; Zhang, L.; Cui, H. The Roles of Sirtuin Family Proteins in Cancer Progression. Cancers. 2019, 11, 1949. [Google Scholar] [CrossRef]
  35. Carafa, V.; Altucci, L.; Nebbioso, A. Dual Tumor Suppressor and Tumor Promoter Action of Sirtuins in Determining Malignant Phenotype. Front Pharmacol. 2019, 10, 38. [Google Scholar] [CrossRef]
  36. Giblin, W.; Lombard, D.B. Sirtuins; Healthspan; and Longevity in Mammals. Handbook of the Biology of Aging; 8th ed.; Kaeberlein, M.R., Martin, M.G.; Academic Press; 2016; Chapter 3; pp. 83-132. [CrossRef]
  37. Kratz, E.M.; Sołkiewicz, K.; Kubis-Kubiak, A.; Piwowar, A. Sirtuins as Important Factors in Pathological States and the Role of Their Molecular Activity Modulators. Int J Mol Sci. 2021, 22, 630. [Google Scholar] [CrossRef] [PubMed]
  38. Vaziri, H.; Dessain, S.K.; Ng, E.E.; Imai, S.I.; Frye, R.A.; Pandita, T.K.; Guarente, L.; Weinberg, R.A. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001, 107, 149–59. [Google Scholar] [CrossRef]
  39. Luo, J.; Nikolaev, A.Y.; Imai, S.; Chen, D.; Su, F.; Shiloh, A.; Guarente, L.; Gu, W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 2001, 107, 137–48. [Google Scholar] [CrossRef]
  40. Deng, CX. SIRT1; is it a tumor promoter or tumor suppressor? Int J Biol Sci. 2009, 5, 147–52. [Google Scholar] [CrossRef]
  41. Ng, S.W.; Mitchell, A.; Kennedy, J.A.; Chen, W.C.; McLeod, J.; Ibrahimova, N.; Arruda, A.; Popescu, A.; Gupta, V.; Schimmer, A.D.; Schuh, A.C.; Yee, K.W.; Bullinger, L.; Herold, T.; Görlich, D.; Büchner, T.; Hiddemann, W.; Berdel, W.E.; Wörmann, B.; Cheok, M.; Preudhomme, C.; Dombret, H.; Metzeler, K.; Buske, C.; Löwenberg, B.; Valk, P.J.; Zandstra, P.W.; Minden, M.D.; Dick, J.E.; Wang, J.C. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016, 540, 433–437. [Google Scholar] [CrossRef]
  42. Li, L.; Osdal, T.; Ho, Y.; Chun, S.; McDonald, T.; Agarwal, P.; Lin, A.; Chu, S.; Qi, J.; Li, L.; Hsieh, Y.T.; Dos Santos, C.; Yuan, H.; Ha, T.Q.; Popa, M.; Hovland, R.; Bruserud, Ø.; Gjertsen, B.T.; Kuo, Y.H.; Chen, W.; Lain, S.; McCormack, E.; Bhatia, R. SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. Cell Stem Cell. 2014, 15, 431–446. [Google Scholar] [CrossRef] [PubMed]
  43. O'Donnell, M.R.; Abboud, C.N.; Altman, J.; Appelbaum, F.R.; Arber, D.A.; Attar, E.; Borate, U.; Coutre, S.E.; Damon, L.E.; Goorha, S.; Lancet, J.; Maness, L.J.; Marcucci, G.; Millenson, M.M.; Moore, J.O.; Ravandi, F.; Shami, P.J.; Smith, B.D.; Stone, R.M.; Strickland, S.A.; Tallman, M.S.; Wang, E.S.; Naganuma, M.; Gregory, K.M. NCCN Clinical Practice Guidelines Acute myeloid leukemia. J Natl Compr Canc Netw. 2012, 10, 984–1021. [Google Scholar] [CrossRef] [PubMed]
  44. Sasca, D.; Hähnel, P.S.; Szybinski, J.; Khawaja, K.; Kriege, O.; Pante, S.V.; Bullinger, L.; Strand, S.; Strand, D.; Theobald, M.; Kindler, T. SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia. Blood. 2014, 124, 121–33. [Google Scholar] [CrossRef]
  45. Daver, N.; Schlenk, R.F.; Russell, N.H.; Levis, M.J. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019, 33, 299–312. [Google Scholar] [CrossRef]
  46. Patel, J.P.; Gönen, M.; Figueroa, M.E.; Fernandez, H.; Sun, Z.; Racevskis, J.; Van Vlierberghe, P.; Dolgalev, I.; Thomas, S.; Aminova, O.; Huberman, K.; Cheng, J.; Viale, A.; Socci, N.D.; Heguy, A.; Cherry, A.; Vance, G.; Higgins, R.R.; Ketterling, R.P.; Gallagher, R.E.; Litzow, M.; van den Brink, M.R.; Lazarus, H.M.; Rowe, J.M.; Luger, S.; Ferrando, A.; Paietta, E.; Tallman, M.S.; Melnick, A.; Abdel-Wahab, O.; Levine, R.L. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012, 366, 1079–89. [Google Scholar] [CrossRef] [PubMed]
  47. Bradbury, C.A.; Khanim, F.L.; Hayden, R.; Bunce, C.M.; White, D.A.; Drayson, M.T.; Craddock, C.; Turner, B.M. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia. 2005, 19, 1751–9. [Google Scholar] [CrossRef]
  48. Li, L.C.; Wang, J.D.; Yang, S.S.; Zhou, Z.; Zeng, Q.F.; Zheng, F. [Establishment of Drug-Resistant Cell Lines of Acute Myeloid Leukemia and Correlation of Sirt1 and PGC-1α Expression Levels with Drug Resistance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022, 30, 704–710. [Google Scholar] [CrossRef]
  49. Tian, W.L.; Guo, R.; Wang, F.; Jiang, Z.X.; Tang, P.; Huang, Y.M.; Sun, L. The IRF9-SIRT1-P53 axis is involved in the growth of human acute myeloid leukemia. Exp Cell Res. 2018, 365, 185–193. [Google Scholar] [CrossRef]
  50. Chen, C.W.; Koche, R.P.; Sinha, A.U.; Deshpande, A.J.; Zhu, N.; Eng, R.; Doench, J.G.; Xu, H.; Chu, S.H.; Qi, J.; Wang, X.; Delaney, C.; Bernt, K.M.; Root, D.E.; Hahn, W.C.; Bradner, J.E.; Armstrong, S.A. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat Med. 2015, 21, 335–43. [Google Scholar] [CrossRef]
  51. Levavasseur, F.; Oussous, S.; Zubaidan, T.; Kosmider, O.; Pendino, F.; Rombaut, D.; Bouscary, D.; Fontenay, M.; Lauret, E.; Dusanter-Fourt, I. FOXP1 regulates oxidative stress; SIRT1 expression; and resistance to chemotherapies in acute myeloid leukemia cells. Blood Adv. 2023, 7, 3265–3275. [Google Scholar] [CrossRef]
  52. Yuan, H.; Wang, Z.; Li, L.; Zhang, H.; Modi, H.; Horne, D.; Bhatia, R.; Chen, W. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood. 2012, 119, 1904–14. [Google Scholar] [CrossRef] [PubMed]
  53. Van Etten, R.A. Aberrant cytokine signaling in leukemia. Oncogene. 2007, 15, 6738–49. [Google Scholar] [CrossRef]
  54. Bartel, D.P.; Chen, C.Z. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet. 2004, 5, 396–400. [Google Scholar] [CrossRef]
  55. Zhou, L.; Fu, L.; Lv, N.; Chen, X.S.; Liu, J.; Li, Y.; Xu, Q.Y.; Huang, S.; Zhang, X.D.; Dou, L.P.; Wang, L.L.; Li, Y.H.; Yu, L. A minicircuitry comprised of microRNA-9 and SIRT1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia. Eur Rev Med Pharmacol Sci. 2017, 21, 786–794. [Google Scholar] [PubMed]
  56. Vaquero, A.; Scher, M.B.; Lee, D.H.; Sutton, A.; Cheng, H.L.; Alt, F.W.; Serrano, L.; Sternglanz, R.; Reinberg, D. SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes Dev. 2006, 20, 1256–61. [Google Scholar] [CrossRef]
  57. Harting, K.; Knöll, B. SIRT2-mediated protein deacetylation: An emerging key regulator in brain physiology and pathology. Eur J Cell Biol. 2010, 89, 262–9. [Google Scholar] [CrossRef] [PubMed]
  58. Ahmed, M.A.; O'Callaghan, C.; Chang, E.D.; Jiang, H.; Vassilopoulos, A. Context-Dependent Roles for SIRT2 and SIRT3 in Tumor Development Upon Calorie Restriction or High Fat Diet. Front Oncol. 2020, 9, 1462. [Google Scholar] [CrossRef]
  59. Chen, G.; Huang, P.; Hu, C. The role of SIRT2 in cancer: A novel therapeutic target. Int J Cancer. 2020, 147, 3297–3304. [Google Scholar] [CrossRef]
  60. Zhang, K.; Sowers, M.L.; Cherryhomes, E.I.; Singh, V.K.; Mishra, A.; Restrepo, B.I.; Khan, A.; Jagannath, C. Sirtuin-dependent metabolic and epigenetic regulation of macrophages during tuberculosis. Front Immunol. 2023, 14, 1121495. [Google Scholar] [CrossRef]
  61. Zhao, D.; Zou, S.W.; Liu, Y.; Zhou, X.; Mo, Y.; Wang, P.; Xu, Y.H.; Dong, B.; Xiong, Y.; Lei, Q.Y.; Guan, K.L. Lysine-5 acetylation negatively regulates lactate dehydrogenase A and is decreased in pancreatic cancer. Cancer Cell. 2013, 23, 464–76. [Google Scholar] [CrossRef]
  62. Kozako, T.; Mellini, P.; Ohsugi, T.; Aikawa, A.; Uchida, Y.I.; Honda, S.I.; Suzuki, T. Novel small molecule SIRT2 inhibitors induce cell death in leukemic cell lines. BMC Cancer. 2018, 18, 791. [Google Scholar] [CrossRef] [PubMed]
  63. Dan, L.; Klimenkova, O.; Klimiankou, M.; Klusman, J.H.; van den Heuvel-Eibrink, M.M.; Reinhardt, D.; Welte, K.; Skokowa, J. The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. Haematologica. 2012, 97, 551–9. [Google Scholar] [CrossRef] [PubMed]
  64. Deng, A.; Ning, Q.; Zhou, L.; Liang, Y. SIRT2 is an unfavorable prognostic biomarker in patients with acute myeloid leukemia. Sci Rep. 2016, 6, 27694. [Google Scholar] [CrossRef] [PubMed]
  65. McMahon, K.A.; Hiew, S.Y.; Hadjur, S.; Veiga-Fernandes, H.; Menzel, U.; Price, A.J.; Kioussis, D.; Williams, O.; Brady, H.J. Mll has a critical role in fetal and adult hematopoietic stem cell self-renewal. Cell Stem Cell. 2007, 1, 338–45. [Google Scholar] [CrossRef] [PubMed]
  66. Jude, C.D.; Climer, L.; Xu, D.; Artinger, E.; Fisher, J.K.; Ernst, P. Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. Cell Stem Cell. 2007, 1, 324–37. [Google Scholar] [CrossRef]
  67. Hao, C.; Shao, X.; Song, J.; Peng, M.; Lao, Y.; Mack, R.; Zhang, L.; Wei, W.; Liu, N.; Wang, T.; Wu, Y.; Feng, L.; Yin, L.; Wang, S.; Sun, X.; Chen, S.; Zhang, J.; Li, B. SIRT2 regulates proliferation and chemotherapy response of MLL-ENL-driven acute myeloid leukemia. Biochem Biophys Res Commun. 2022, 596, 36–42. [Google Scholar] [CrossRef]
  68. Xu, H.; Li, Y.; Chen, L.; Wang, C.; Wang, Q.; Zhang, H.; Lin, Y.; Li, Q.; Pang, T. SIRT2 mediates multidrug resistance in acute myelogenous leukemia cells via ERK1/2 signaling pathway. Int J Oncol. 2016, 48, 613–23. [Google Scholar] [CrossRef]
  69. Yip, P.Y. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer. Transl Lung Cancer Res. 2015, 4, 165–76. [Google Scholar] [CrossRef] [PubMed]
  70. Luo, Y.; Zhao, H.; Zhu, J.; Zhang, L.; Zha, J.; Zhang, L.; Ding, Y.; Jian, X.; Xia, J.; Xu, B.; Qi, Z. SIRT2 inhibitor SirReal2 enhances anti-tumor effects of PI3K/mTOR inhibitor VS-5584 on acute myeloid leukemia cells. Cancer Med. 2023, 12, 18901–18917. [Google Scholar] [CrossRef]
  71. Dan, L.; Gigina, A.; Welte, K.; Skokowa, J. Nampt/SIRT2 Hyperactivation Lead to Activation of ß-Catenin: a Possible Mechanism of Leukomogenic Transformation In CN Patients. Blood. 2010, 116, 1486. [Google Scholar] [CrossRef]
  72. Xu, S.N.; Wang, T.S.; Li, X.; Wang, Y.P. SIRT2 activates G6PD to enhance NADPH production and promote leukaemia cell proliferation. Sci Rep. 2016, 6, 32734. [Google Scholar] [CrossRef]
  73. Russo, C.; Maugeri, A.; De Luca, L.; Gitto, R.; Lombardo, G.E.; Musumeci, L.; De Sarro, G.; Cirmi, S.; Navarra, M. The SIRT2 Pathway Is Involved in the Antiproliferative Effect of Flavanones in Human Leukemia Monocytic THP-1 Cells. Biomedicines. 2022, 10, 2383. [Google Scholar] [CrossRef] [PubMed]
  74. Zhao, L.; Qi, Y.; Xu, L.; Tao, X.; Han, X.; Yin, L.; Peng, J. MicroRNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting Nrf2 and Sirt2. Redox Biol. 2018, 15, 284–296. [Google Scholar] [CrossRef] [PubMed]
  75. Havelange, V.; Stauffer, N.; Heaphy, C.C.; Volinia, S.; Andreeff, M.; Marcucci, G.; Croce, C.M.; Garzon, R. Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling. Cancer. 2011, 117, 4696–706. [Google Scholar] [CrossRef]
  76. Zhang, J.; Xiang, H.; Liu, J.; Chen, Y.; He, R.R.; Liu, B. Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target. Theranostics. 2020, 10, 8315–8342. [Google Scholar] [CrossRef]
  77. Chen, Y.; Fu, L.L.; Wen, X.; Wang, X.Y.; Liu, J.; Cheng, Y.; Huang, J. Sirtuin-3 (SIRT3); a therapeutic target with oncogenic and tumor-suppressive function in cancer. Cell Death Dis. 2014, 5, e1047. [Google Scholar] [CrossRef]
  78. Zhao, K.; Zhou, Y.; Qiao, C.; Ni, T.; Li, Z.; Wang, X.; Guo, Q.; Lu, N.; Wei, L. Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells. J Hematol Oncol. 2015, 8, 41. [Google Scholar] [CrossRef]
  79. Wei, L.; Zhou, Y.; Dai, Q.; Qiao, C.; Zhao, L.; Hui, H.; Lu, N.; Guo, Q.L. Oroxylin A induces dissociation of hexokinase II from the mitochondria and inhibits glycolysis by SIRT3-mediated deacetylation of cyclophilin D in breast carcinoma. Cell Death Dis. 2013, 4, e601. [Google Scholar] [CrossRef] [PubMed]
  80. Bergaggio, E.; Riganti, C.; Garaffo, G.; Vitale, N.; Mereu, E.; Bandini, C.; Pellegrino, E.; Pullano, V.; Omedè, P.; Todoerti, K.; Cascione, L.; Audrito, V.; Riccio, A.; Rossi, A.; Bertoni, F.; Deaglio, S.; Neri, A.; Palumbo, A.; Piva, R. IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies. Blood. 2019, 133, 156–167. [Google Scholar] [CrossRef]
  81. O'Brien, C.; Berman, J.; Culp-Hill, R.; Reisz, J.; Ling, T.; Rondeau, V.; Li, M.; Yang, M.; Hong, J.Y.; Lin, H.; Melnick, A.; Arruda, A.; Minden, M.D.; D'Alessandro, A.; Jones, C.L. Sirtuin 3 Inhibition Targets AML Stem Cells through Perturbation of Fatty Acid Oxidation. Blood. 2021, 138 (Suppl. S1). [Google Scholar] [CrossRef]
  82. O'Brien, C.; Ling, T.; Berman, J.M.; Culp-Hill, R.; Reisz, J.A.; Rondeau, V.; Jahangiri, S.; St-Germain, J.; Macwan, V.; Astori, A.; Zeng, A.; Hong, J.Y.; Li, M.; Yang, M.; Jana, S.; Gamboni, F.; Tsao, E.; Liu, W.; Dick, J.E.; Lin, H.; Melnick, A.; Tikhonova, A.; Arruda, A.; Minden, M.D.; Raught, B.; D'Alessandro, A.; Jones, C.L. Simultaneous inhibition of Sirtuin 3 and cholesterol homeostasis targets acute myeloid leukemia stem cells by perturbing fatty acid β-oxidation and inducing lipotoxicity. Haematologica. 2023, 108, 2343–2357. [Google Scholar] [CrossRef]
  83. Ma, J.; Liu, B.; Yu, D.; Zuo, Y.; Cai, R.; Yang, J.; Cheng, J. SIRT3 deacetylase activity confers chemoresistance in AML via regulation of mitochondrial oxidative phosphorylation. Br J Haematol. 2019, 187, 49–64. [Google Scholar] [CrossRef] [PubMed]
  84. Chen, Y.; Jiang, Z.; Yang, Y.; Zhang, C.; Liu, H.; Wan, J. The functions and mechanisms of post-translational modification in protein regulators of RNA methylation: Current status and future perspectives. Int J Biol Macromol. 2023, 253, 126773. [Google Scholar] [CrossRef] [PubMed]
  85. Zhang, Y.; Shen, Y.; Wei, W.; Wang, W.; Jiang, D.; Ren, Y.; Peng, Z.; Fan, Q.; Cheng, J.; Ma, J. Dysregulation of SIRT3 SUMOylation Confers AML Chemoresistance via Controlling HES1-Dependent Fatty Acid Oxidation. Int J Mol Sci. 2022, 23, 8282. [Google Scholar] [CrossRef] [PubMed]
  86. Ma, J.; Liu, B.; Yu, D.; Tam, W.; Yang, J.; Cheng, J. SIRT3 Sumoylation Contributes to Chemoresistance in AML. Blood. 2018, 132 (Suppl. S1). [Google Scholar] [CrossRef]
  87. Strzałka, P.; Krawiec, K.; Jarych, D.; Wiśnik, A.; Soin, M.; Góralska, M.; Mikulski, D.; Czemerska, M.; Zawlik, I.; Pluta, A.; Wierzbowska, A. Assessment of SIRT1-SIRT7 and TP53 Genes Expression in Patients with Acute Myeloid Leukemia. Blood. 2023, 142 (Suppl. S1). [Google Scholar] [CrossRef]
  88. Goes, J.V.C.; Carvalho, L.G.; de Oliveira, R.T.G.; Melo, M.M.L.; Novaes, L.A.C.; Moreno, D.A.; Gonçalves, P.G.; Montefusco-Pereira, C.V.; Pinheiro, R.F.; Ribeiro, Junior H. L. Role of Sirtuins in the Pathobiology of Onco-Hematological Diseases: A PROSPERO-Registered Study and In Silico Analysis. Cancers. 2022, 14, 4611. [Google Scholar] [CrossRef]
  89. Haigis, M.C.; Mostoslavsky, R.; Haigis, K.M.; Fahie, K.; Christodoulou, D.C.; Murphy, A.J.; Valenzuela, D.M.; Yancopoulos, G.D.; Karow, M.; Blander, G.; Wolberger, C.; Prolla, T.A.; Weindruch, R.; Alt, F.W.; Guarente, L. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell. 2006, 126, 941–54. [Google Scholar] [CrossRef]
  90. Huang, G.; Zhu, G. Sirtuin-4 (SIRT4), a therapeutic target with oncogenic and tumor-suppressive activity in cancer. Onco Targets Ther. 2018, 11, 3395–3400. [Google Scholar] [CrossRef]
  91. Frye, RA. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem Biophys Res Commun. 1999, 260, 273–9. [Google Scholar] [CrossRef]
  92. Jeong, S.M.; Xiao, C.; Finley, L.W.; Lahusen, T.; Souza, A.L.; Pierce, K.; Li, Y.H.; Wang, X.; Laurent, G.; German, N.J.; Xu, X.; Li, C.; Wang, R.H. , Lee, J.; Csibi, A.; Cerione, R.; Blenis, J.; Clish, C.B.; Kimmelman, A.; Deng, C.X.; Haigis, M.C. SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell. 2013, 23, 450–63. [Google Scholar] [CrossRef]
  93. Jeong, S.M.; Lee, A.; Lee, J.; Haigis, M.C. SIRT4 protein suppresses tumor formation in genetic models of Myc-induced B cell lymphoma. J Biol Chem. 2014, 289, 4135–44. [Google Scholar] [CrossRef] [PubMed]
  94. Csibi, A.; Fendt, S.M.; Li, C.; Poulogiannis, G.; Choo, A.Y.; Chapski, D.J.; Jeong, S.M.; Dempsey, J.M.; Parkhitko, A.; Morrison, T.; Henske, E.P.; Haigis, M.C.; Cantley, L.C.; Stephanopoulos, G.; Yu, J.; Blenis, J. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell. 2013, 153, 840–54. [Google Scholar] [CrossRef]
  95. Shi, Q.; Liu, T.; Zhang, X.; Geng, J.; He, X.; Nu, M.; Pang, D. Decreased sirtuin 4 expression is associated with poor prognosis in patients with invasive breast cancer. Oncol Lett. 2016, 12, 2606–2612. [Google Scholar] [CrossRef] [PubMed]
  96. Lai, X.; Yu,, Z. ; Chen X.; Huang, G. SIRT4 is upregulated in Chinese patients with esophageal cancer. Int J Clin Exp Pathol. 2016, 9, 10543–10549. [Google Scholar]
  97. Bradbury, C.A.; Khanim, F.L.; Hayden, R.; Bunce, C.M.; White, D.A.; Drayson, M.T.; Craddock, C.; Turner, B.M. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia. 2005, 19, 1751–9. [Google Scholar] [CrossRef]
  98. Strzałka, P.; Krawiec, K.; Jarych, D.; Wiśnik, A.; Góralska, M.; Soin, M.; Mikulski, D.; Czemerska, M.; Zawlik, I.; Pluta, A.; Wierzbowska, A. Evaluation of Sirtuins and TP53 Gene Expression and Their Impact on Prognosis in Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2023, 23 (Suppl. S1), S314–S315. [Google Scholar] [CrossRef]
  99. Vaquero, A.; Reinberg, D. Sirtuins in Biology and Disease. Epigenetics in Biology and Medicine; 1st ed.; Esteller; M.; CRC Press; 2009; Chapter 6; pp. 73-104. [CrossRef]
  100. Yue, X.; Shi, Y.; Luo, Q. Advances of SIRT4 in cancer metabolism and therapy. Pediatr Discov. 2023, 1, e17. [Google Scholar] [CrossRef]
  101. Jeong, S.M.; Hwang, S.; Seong, R.H. SIRT4 regulates cancer cell survival and growth after stress. Biochem Biophys Res Commun. 2016, 470, 251–256. [Google Scholar] [CrossRef]
  102. Du, J.; Zhou, Y.; Su, X.; Yu, J.J.; Khan, S.; Jiang, H.; Kim, J.; Woo, J.; Kim, J.H.; Choi, B.H.; He, B.; Chen, W.; Zhang, S.; Cerione, R.A.; Auwerx, J.; Hao, Q.; Lin, H. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science. 2011, 334, 806–9. [Google Scholar] [CrossRef]
  103. Nishida, Y.; Rardin, M.J.; Carrico, C.; He, W.; Sahu, A.K.; Gut, P.; Najjar, R.; Fitch, M.; Hellerstein, M.; Gibson, B.W.; Verdin, E. SIRT5 Regulates both Cytosolic and Mitochondrial Protein Malonylation with Glycolysis as a Major Target. Mol Cell. 2015, 59, 321–32. [Google Scholar] [CrossRef] [PubMed]
  104. Tan, M.; Peng, C.; Anderson, K.A.; Chhoy, P.; Xie, Z.; Dai, L.; Park, J.; Chen, Y.; Huang, H.; Zhang, Y.; Ro, J.; Wagner, G.R.; Green, M.F.; Madsen, A.S.; Schmiesing, J.; Peterson, B.S.; Xu, G.; Ilkayeva, O.R.; Muehlbauer, M.J.; Braulke, T.; Mühlhausen, C.; Backos, D.S.; Olsen, C.A.; McGuire, P.J.; Pletcher, S.D.; Lombard, D.B.; Hirschey, M.D.; Zhao, Y. Lysine glutarylation is a protein posttranslational modification regulated by SIRT5. Cell Metab. 2014, 19, 605–17. [Google Scholar] [CrossRef] [PubMed]
  105. Park, J.; Chen, Y.; Tishkoff, D.X.; Peng, C.; Tan, M.; Dai, L.; Xie, Z.; Zhang, Y.; Zwaans, B.M.; Skinner, M.E.; Lombard, D.B.; Zhao, Y. SIRT5-mediated lysine desuccinylation impacts diverse metabolic pathways. Mol Cell. 2013, 50, 919–30. [Google Scholar] [CrossRef]
  106. Wątroba, M.; Szukiewicz, D. Sirtuins in the biology of aging. Sirtuin Biology in Medicine; Maiese, K.; Academic Press, 2021; Chapter 5, pp. 79-90. [CrossRef]
  107. Zhao, L.; Cao, J.; Hu, K.; He, X.; Yun, D.; Tong, T.; Han, L. Sirtuins and their Biological Relevance in Aging and Age-Related Diseases. Aging Dis. 2020, 11, 927–945. [Google Scholar] [CrossRef]
  108. Liu, B.; Che, W.; Zheng, C.; Liu, W.; Wen, J.; Fu, H.; Tang, K.; Zhang, J.; Xu, Y. SIRT5: a safeguard against oxidative stress-induced apoptosis in cardiomyocytes. Cell Physiol Biochem. 2013, 32, 1050–9. [Google Scholar] [CrossRef]
  109. Liang, F.; Wang, X.; Ow, S.H.; Chen, W.; Ong, W.C. Sirtuin 5 is Anti-apoptotic and Anti-oxidative in Cultured SH-EP Neuroblastoma Cells. Neurotox Res. 2017, 31, 63–76. [Google Scholar] [CrossRef] [PubMed]
  110. Li, W.; Yang, Y.; Li, Y.; Zhao, Y.; Jiang, H. Sirt5 Attenuates Cisplatin-Induced Acute Kidney Injury through Regulation of Nrf2/HO-1 and Bcl-2. Biomed Res Int. 2019, 2019, 4745132. [Google Scholar] [CrossRef]
  111. Krawiec, K.; Strzałka, P.; Czemerska, M.; Wiśnik, A.; Zawlik, I.; Wierzbowska, A.; Pluta, A. Targeting Apoptosis in AML: Where Do We Stand? Cancers. 2022, 14, 4995. [Google Scholar] [CrossRef]
  112. Li, M.; Melnick, A.M. Non-oncogene Addiction to SIRT5 in Acute Myeloid Leukemia. Blood Cancer Discov. 2021, 2, 198–200. [Google Scholar] [CrossRef]
  113. Yan, D.; Franzini, A.; Pomicter, A.D.; Halverson, B.J.; Antelope, O.; Mason, C.C.; Ahmann, J.M.; Senina, A.V.; Vellore, N.A.; Jones, C.L.; Zabriskie, M.S.; Than, H.; Xiao, M.J.; van Scoyk, A.; Patel, A.B.; Clair, P.M.; Heaton, W.L.; Owen, S.C.; Andersen, J.L.; Egbert, C.M.; Reisz, J.A.; D'Alessandro, A.; Cox, J.E.; Gantz, K.C.; Redwine, H.M.; Iyer, S.M.; Khorashad, J.S.; Rajabi, N.; Olsen, C.A.; O'Hare, T.; Deininger, M.W. SIRT5 is a druggable metabolic vulnerability in acute myeloid leukemia. Blood Cancer Discov. 2021, 2, 266–287. [Google Scholar] [CrossRef]
  114. Yan, D.; Pomicter, A.D.; Heaton, W.L.; Mason, C.C.; Ahmann, J.; Senina, A.; Franzini, A.; Halverson, B.; Than, H.; Clair, P.M.; Khorashad, J.S.; O'Hare, T.; Deininger, M.W. SIRT5 As a Therapeutic Target in Acute Myeloid Leukemia. Blood. 2018, 132 (Suppl. S1). [Google Scholar] [CrossRef]
  115. Rajabi, N.; Hansen, T.N.; Nielsen, A.L.; Nguyen, H.T.; Bæk, M.; Bolding, J.E.; Bahlke, O.Ø.; Petersen, S.E.G.; Bartling, C.R.O.; Strømgaard, K.; Olsen, C.A. Angew. Chem. Int. Ed. 2022, 61, e202115805. [CrossRef]
  116. Arévalo, C.M.; Cruz-Rodriguez, N.; Quijano, S.; Fiorentino, S. Plant-derived extracts and metabolic modulation in leukemia: a promising approach to overcome treatment resistance. Front Mol Biosci. 2023, 10, 1229760. [Google Scholar] [CrossRef]
  117. Wang, M.; Shi, W.; Zhu, R.; Small, D.; Li, L.; Ma, S.; Hu, Y. Targeting SIRT5 By Succinylating Hadha Synergizes with Venetoclax in Acute Myeloid Leukemia. Blood. 2023, 142 (Suppl. S1). [Google Scholar] [CrossRef]
  118. Salehi, B.; Mishra, A.P.; Nigam, M.; Sener, B.; Kilic, M.; Sharifi-Rad, M.; Fokou, P.V.T.; Martins, N.; Sharifi-Rad, J. Resveratrol: A Double-Edged Sword in Health Benefits. Biomedicines. 2018, 6, 91. [Google Scholar] [CrossRef]
  119. Ozkan, T.; Koc, A.; Karabay, A.Z.; Hekmatshoar, Y.; Sunguroglu, A. An investigation on the effects of SIRT5 modulators on SIRT5 and Cytochrome C protein expressions in K562 chronic myeloid leukemia cell line. J. Fac. Pharm. 2022, 46, 805–816. [Google Scholar] [CrossRef]
  120. Bateman, B.; Bates, B.; Deininger, M.; Zhao, H.G.G. Chronic Mitochondrial Dysfunction Renders Acute Myeloid Leukemia Resistant to Multipronged Inhibition of Mitochondrial Metabolism. Blood. 2023, 142 (Suppl. S1). [Google Scholar] [CrossRef]
  121. Li, F.; He, X.; Ye, D.; Lin, Y.; Yu, H.; Yao, C.; Huang, L.; Zhang, J.; Wang, F.; Xu, S.; Wu, X.; Liu, L.; Yang, C.; Shi, J.; He, X.; Liu, J.; Qu, Y.; Guo, F.; Zhao, J.; Xu, W.; Zhao, S. NADP(+)-IDH Mutations Promote Hypersuccinylation that Impairs Mitochondria Respiration and Induces Apoptosis Resistance. Mol Cell. 2015, 60, 661–75. [Google Scholar] [CrossRef] [PubMed]
  122. Xu, W.; Yang, H.; Liu, Y.; Yang, Y.; Wang, P.; Kim, S.H.; Ito, S.; Yang, C.; Wang, P.; Xiao, M.T.; Liu, L.X.; Jiang, W.Q.; Liu, J.; Zhang, J.Y.; Wang, B.; Frye, S.; Zhang, Y.; Xu, Y.H.; Lei, Q.Y.; Guan, K.L.; Zhao, S.M.; Xiong, Y. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011, 19, 17–30. [Google Scholar] [CrossRef]
  123. Fabbrizi, E.; Fiorentino, F.; Carafa, V.; Altucci, L.; Mai, A.; Rotili, D. Emerging Roles of SIRT5 in Metabolism, Cancer, and SARS-CoV-2 Infection. Cells. 2023, 12, 852. [Google Scholar] [CrossRef]
  124. Frye, R.A. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun. 2000, 273, 793–8. [Google Scholar] [CrossRef] [PubMed]
  125. Beauharnois, J.M.; Bolívar, B.E.; Welch, J.T. Sirtuin 6: a review of biological effects and potential therapeutic properties. Mol Biosyst. 2013, 9, 1789–806. [Google Scholar] [CrossRef] [PubMed]
  126. Klein, M.A.; Denu, J.M. Biological and catalytic functions of sirtuin 6 as targets for small-molecule modulators. J Biol Chem. 2020, 295, 11021–11041. [Google Scholar] [CrossRef]
  127. Banerjee, A.; Pavane, M.S.; Banu, L.H.; Gopikar, A.S.R.; Elizabeth, K.R.; Pathak, S. Traditional medicine for aging-related disorders: Implications for drug discovery. Stem Cells and Aging; Pathak, S.; Banerjee, A. Academic Press, 2021; Chapter 20, pp. 281-297. [CrossRef]
  128. Zhang, J.; Yin, X.J.; Xu, C.J.; Ning, Y.X.; Chen, M.; Zhang, H.; Chen, S.F.; Yao, L.Q. The histone deacetylase SIRT6 inhibits ovarian cancer cell proliferation via down-regulation of Notch 3 expression. Eur Rev Med Pharmacol Sci. 2015, 19, 818–24. [Google Scholar] [PubMed]
  129. Choe, M.; Brusgard, J.L.; Chumsri, S.; Bhandary, L.; Zhao, X.F.; Lu, S.; Goloubeva, O.G.; Polster, B.M.; Fiskum, G.M.; Girnun, G.D.; Kim, M.S.; Passaniti, A. The RUNX2 Transcription Factor Negatively Regulates SIRT6 Expression to Alter Glucose Metabolism in Breast Cancer Cells. J Cell Biochem. 2015, 116, 2210–26. [Google Scholar] [CrossRef]
  130. Qi, J.; Cui, C.; Deng, Q.; Wang, L.; Chen, R.; Zhai, D.; Xie, L.; Yu, J. Downregulated SIRT6 and upregulated NMNAT2 are associated with the presence; depth and stage of colorectal cancer. Oncol Lett. 2018, 16, 5829–5837. [Google Scholar] [CrossRef]
  131. Min, L.; Ji, Y.; Bakiri, L.; Qiu, Z.; Cen, J.; Chen, X.; Chen, L.; Scheuch, H.; Zheng, H.; Qin, L.; Zatloukal, K.; Hui, L.; Wagner, E.F. Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat Cell Biol. 2012, 14, 1203–11. [Google Scholar] [CrossRef]
  132. Barretina, J.; Caponigro, G.; Stransky, N.; Venkatesan, K.; Margolin, A.A.; Kim, S.; Wilson, C.J.; Lehár, J.; Kryukov, G.V.; Sonkin, D.; Reddy, A.; Liu, M.; Murray, L.; Berger, M.F.; Monahan, J.E.; Morais, P.; Meltzer, J.; Korejwa, A.; Jané-Valbuena, J.; Mapa, F.A.; Thibault, J.; Bric-Furlong, E.; Raman, P.; Shipway, A.; Engels, I.H.; Cheng, J.; Yu, G.K.; Yu, J.; Aspesi, P. Jr.; de Silva, M.; Jagtap, K.; Jones, M.D.; Wang, L.; Hatton, C.; Palescandolo, E.; Gupta, S.; Mahan, S.; Sougnez, C.; Onofrio, R.C.; Liefeld, T.; MacConaill, L.; Winckler, W.; Reich, M.; Li, N.; Mesirov, J.P.; Gabriel, S.B.; Getz, G.; Ardlie, K.; Chan, V.; Myer, V.E.; Weber, B.L.; Porter, J.; Warmuth, M.; Finan, P.; Harris, J.L.; Meyerson, M.; Golub, T.R.; Morrissey, M.P.; Sellers, W.R.; Schlegel, R.; Garraway, L.A. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012, 483, 603–7. [Google Scholar] [CrossRef]
  133. Lai, CC.; Lin, P.M.; Lin, S.F.; Hsu, C.H.; Lin, H.C.; Hu, M.L.; Hsu, C.M.; Yang, M.Y. Altered expression of SIRT gene family in head and neck squamous cell carcinoma. Tumour Biol. 2013, 34, 1847–54. [Google Scholar] [CrossRef]
  134. Lefort, K.; Brooks, Y.; Ostano, P.; Cario-André, M.; Calpini, V.; Guinea-Viniegra, J.; Albinger-Hegyi, A.; Hoetzenecker, W.; Kolfschoten, I.; Wagner, E.F.; Werner, S.; Dotto, G.P. A miR-34a-SIRT6 axis in the squamous cell differentiation network. EMBO J. 2013, 32, 2248–63. [Google Scholar] [CrossRef]
  135. Cea, M.; Cagnetta, A.; Adamia, S.; Acharya, C.; Tai, Y.T.; Fulciniti, M.; Ohguchi, H.; Munshi, A.; Acharya, P.; Bhasin, M.K.; Zhong, L.; Carrasco, R.; Monacelli, F.; Ballestrero, A.; Richardson, P.; Gobbi, M.; Lemoli, R.M.; Munshi, N.; Hideshima, T.; Nencioni, A.; Chauhan, D.; Anderson, K.C. Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood. 2016, 127, 1138–50. [Google Scholar] [CrossRef]
  136. Wang, J.C.; Kafeel, M.I.; Avezbakiyev, B.; Chen, C.; Sun, Y.; Rathnasabapathy, C.; Kalavar, M.; He, Z.; Burton, J.; Lichter, S. Histone deacetylase in chronic lymphocytic leukemia. Oncology. 2011, 81, 325–9. [Google Scholar] [CrossRef] [PubMed]
  137. Cagnetta, A.; Soncini, D.; Orecchioni, S.; Talarico, G.; Minetto, P.; Guolo, F.; Retali, V.; Colombo, N.; Carminati, E.; Clavio, M.; Miglino, M.; Bergamaschi, M.; Nahimana, A.; Duchosal, M.; Todoerti, K.; Neri, A.; Passalacqua, M.; Bruzzone, S.; Nencioni, A.; Bertolini, F.; Gobbi, M.; Lemoli, R.M.; Cea, M. Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents. Haematologica. 2018, 103, 80–90. [Google Scholar] [CrossRef] [PubMed]
  138. Cea, M.; Cagnetta, A.; Soncini, D.; Minetto, P.; Lovera, D.; Guolo, F.; Colombo, N.; Ballerini, F.; Clavio, M.; Miglino, M.; Gobbi, M.; Lemoli, R.M. SIRT6 Inhibition As a Novel Approach for Treating Acute Myeloid Leukemia. Blood. 2016, 128, 5222. [Google Scholar] [CrossRef]
  139. Cea, M.; Cagnetta, A.; Lovera, D.; Grasso, R.; Colombo, N.; Bergamaschi, M.; Aquino, S.; Guolo, F.; Minetto, P.; Ballerini, F.; Canepa, L.; Adamia, S.; Nencioni, A.; Pierri, I.; Clavio, M.; Miglino, M.; Gobbi, M.; Lemoli, R.M. A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia. Blood. 2015, 126, 1375. [Google Scholar] [CrossRef]
  140. Hubner, S.E.; de Camargo Magalhães, E.S.; Hoff, F.W.; Brown, B.D.; Qiu, Y.; Horton, T.M.; Kornblau, S.M. DNA Damage Response-Related Proteins Are Prognostic for Outcome in Both Adult and Pediatric Acute Myelogenous Leukemia Patients: Samples from Adults and from Children Enrolled in a Children's Oncology Group Study. Int J Mol Sci. 2023, 24, 5898. [Google Scholar] [CrossRef]
  141. Carraway, H.E.; Malkaram, S.A.; Cen, Y.; Shatnawi, A.; Fan, J.; Ali, H.E.A.; Abd Elmageed, Z.Y.; Buttolph, T.; Denvir, J.; Primerano, D.A.; Fandy, T.E. Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia. Sci Rep. 2020, 10, 10325. [Google Scholar] [CrossRef]
  142. Zhang, Y.; Huang, Z.; Sheng, F.; Yin, Z. MYC upregulated LINC00319 promotes human acute myeloid leukemia (AML) cells growth through stabilizing SIRT6. Biochem Biophys Res Commun. 2019, 509, 314–321. [Google Scholar] [CrossRef]
  143. Zhang, P.; Brinton, L.T.; Williams, K.; Sher, S.; Orwick, S.; Tzung-Huei, L.; Mims, A.S.; Coss, C.C.; Kulp, S.K.; Youssef, Y.; Chan, W.K.; Mitchell, S.; Mustonen, A.; Cannon, M.; Phillips, H.; Lehman, A.M.; Kauffman, T.; Beaver, L.; Canfield, D.; Grieselhuber, N.R.; Alinari, L.; Sampath, D.; Yan, P.; Byrd, J.C.; Blachly, J.S.; Lapalombella, R. Targeting DNA Damage Repair Functions of Two Histone Deacetylases; HDAC8 and SIRT6; Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition. Clin Cancer Res. 2021, 27, 2352–2366. [Google Scholar] [CrossRef]
  144. Shi, X.; Jiang, Y.; Kitano, A.; Hu, T.; Murdaugh, R.L.; Li, Y.; Hoegenauer, K.A.; Chen, R.; Takahashi, K.; Nakada, D. Nuclear NAD+ homeostasis governed by NMNAT1 prevents apoptosis of acute myeloid leukemia stem cells. Sci Adv. 2021, 7, eabf3895. [Google Scholar] [CrossRef]
  145. Yang, X.; Wang, X.; Yang, Y.; Li, Z.; Chen, Y.; Shang, S.; Wang, Y. DNMT3A mutation promotes leukemia development through NAM-NAD metabolic reprogramming. J Transl Med. 2023, 21, 481. [Google Scholar] [CrossRef] [PubMed]
  146. Blank, M.F.; Grummt, I. The seven faces of SIRT7. Transcription. 2017, 8, 67–74. [Google Scholar] [CrossRef] [PubMed]
  147. Vazquez, B.N.; Thackray, J.K.; Simonet, N.G.; Kane-Goldsmith, N.; Martinez-Redondo, P.; Nguyen, T.; Bunting, S.; Vaquero, A.; Tischfield, J.A.; Serrano, L. SIRT7 promotes genome integrity and modulates non-homologous end joining DNA repair. EMBO J. 2016, 35, 1488–503. [Google Scholar] [CrossRef] [PubMed]
  148. Li, L.; Shi, L.; Yang, S.; Yan, R.; Zhang, D.; Yang, J.; He, L.; Li, W.; Yi, X.; Sun, L.; Liang, J.; Cheng, Z.; Shi, L.; Shang, Y.; Yu, W. SIRT7 is a histone desuccinylase that functionally links to chromatin compaction and genome stability. Nat Commun. 2016, 7, 12235. [Google Scholar] [CrossRef]
  149. Ianni, A.; Hoelper, S.; Krueger, M.; Braun, T.; Bober, E. Sirt7 stabilizes rDNA heterochromatin through recruitment of DNMT1 and Sirt1. Biochem Biophys Res Commun. 2017, 492, 434–440. [Google Scholar] [CrossRef]
  150. Ianni, A.; Kumari, P.; Tarighi, S.; Braun, T.; Vaquero, A. SIRT7: a novel molecular target for personalized cancer treatment? Oncogene 2024, 43, 993–1006. [Google Scholar] [CrossRef]
  151. Barber, M.F.; Michishita-Kioi, E.; Xi, Y.; Tasselli, L.; Kioi, M.; Moqtaderi, Z.; Tennen, R.I.; Paredes, S.; Young, N.L.; Chen, K.; Struhl, K.; Garcia, B.A.; Gozani, O.; Li, W.; Chua, K.F. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature. 2012, 487, 114–8. [Google Scholar] [CrossRef]
  152. Li, L.; Bhatia, R. The controversial role of Sirtuins in tumorigenesis - SIRT7 joins the debate. Cell Res. 2013, 23, 10–2. [Google Scholar] [CrossRef]
  153. Ford, E.; Voit, R.; Liszt, G.; Magin, C.; Grummt, I.; Guarente, L. Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes Dev. 2006, 20, 1075–80. [Google Scholar] [CrossRef]
  154. Malik, S.; Villanova, L.; Tanaka, S.; Aonuma, M.; Roy, N.; Berber, E.; Pollack, J.R.; Michishita-Kioi, E.; Chua, K.F. SIRT7 inactivation reverses metastatic phenotypes in epithelial and mesenchymal tumors. Sci Rep. 2015, 5, 9841. [Google Scholar] [CrossRef]
  155. Poniewierska-Baran. A.; Warias, P.; Zgutka, K. Sirtuins (SIRTs) As a Novel Target in Gastric Cancer. Int J Mol Sci. 2022, 23, 15119. [Google Scholar] [CrossRef]
  156. Kim, J.K.; Noh, J.H.; Jung, K.H.; Eun, J.W.; Bae, H.J.; Kim, M.G.; Chang, Y.G.; Shen, Q.; Park, W.S.; Lee, J.Y.; Borlak, J.; Nam, S.W. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology. 2013, 57, 1055–67. [Google Scholar] [CrossRef]
  157. Wang, H.L.; Lu, R.Q.; Xie, S.H.; Zheng, H.; Wen, X.M.; Gao, X.; Guo, L. SIRT7 Exhibits Oncogenic Potential in Human Ovarian Cancer Cells. Asian Pac J Cancer Prev. 2015, 16, 3573–7. [Google Scholar] [CrossRef]
  158. Aljada, A.; Saleh, A.M.; Alkathiri, M.; Shamsa, H.B.; Al-Bawab, A.; Nasr, A. Altered Sirtuin 7 Expression is Associated with Early Stage Breast Cancer. Breast Cancer (Auckl). 2015, 9, 3–8. [Google Scholar] [CrossRef] [PubMed]
  159. Shi, H.; Ji, Y.; Zhang, D.; Liu, Y.; Fang, P. MicroRNA-3666-induced suppression of SIRT7 inhibits the growth of non-small cell lung cancer cells. Oncol Rep. 2016, 36, 3051–3057. [Google Scholar] [CrossRef]
  160. Li, W.; Zhu, D.; Qin, S. SIRT7 suppresses the epithelial-to-mesenchymal transition in oral squamous cell carcinoma metastasis by promoting SMAD4 deacetylation. J Exp Clin Cancer Res. 2018, 37, 148. [Google Scholar] [CrossRef] [PubMed]
  161. Raza, U.; Tang, X.; Liu, Z.; Liu, B. SIRT7: the seventh key to unlocking the mystery of aging. Physiol Rev. 2024, 104, 253–280. [Google Scholar] [CrossRef]
  162. Wang, Y.; Maruichi, A.; Song, Z.; Greenberg, P.; Chen, D. SIRT7 improves hematopoiesis in myelodysplastic syndrome through regulating mitochondrial stress. Experimental Hematology. 2023, 124, S157. [Google Scholar]
  163. Nowicki, M.; Wierzbowska, A.; Stec-Martyna, E.; Kulczycka-Wojdala, D.; Nowicki, G.; Szmigielska-Kapłon, A. SIRT1-SIRT7 Expression in Patients with Lymphoproliferative Disorders Undergoing Hematopoietic Stem Cell Mobilization. Cancers. 2022, 14, 1213. [Google Scholar] [CrossRef]
  164. Kaiser, A.; Schmidt, M.; Huber, O.; Frietsch, J.J.; Scholl, S.; Heidel, F.H.; Hochhaus, A.; Müller, J.P.; Ernst, T. SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders. Leukemia. 2020, 34, 2206–2216. [Google Scholar] [CrossRef]
  165. Metzeler, K.H.; Hummel, M.; Bloomfield, C.D.; Spiekermann, K.; Braess, J.; Sauerland, M.C.; Heinecke, A.; Radmacher, M.; Marcucci, G.; Whitman, S.P.; Maharry, K.; Paschka, P.; Larson, R.A.; Berdel, W.E.; Büchner, T.; Wörmann, B.; Mansmann, U.; Hiddemann, W.; Bohlander, S.K.; Buske, C.; Cancer and Leukemia Group B; German AML Cooperative Group. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood. 2008, 112, 4193–201. [Google Scholar] [CrossRef]
  166. Vakhrusheva, O.; Smolka, C.; Gajawada, P.; Kostin, S.; Boettger, T.; Kubin, T.; Braun, T.; Bober, E. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ Res. 2008, 102, 703–10. [Google Scholar] [CrossRef] [PubMed]
  167. Lee, N.; Kim, D.K.; Kim, E.S.; Park, S.J.; Kwon, J.H.; Shin, J.; Park, S.M.; Moon, Y.H.; Wang, H.J.; Gho, Y.S.; Choi, K.Y. Comparative interactomes of SIRT6 and SIRT7: Implication of functional links to aging. Proteomics. 2014, 14, 1610–22. [Google Scholar] [CrossRef] [PubMed]
  168. Ianni, A.; Kumari, P.; Tarighi, S.; Simonet, N.G.; Popescu, D.; Guenther, S.; Hölper, S.; Schmidt, A.; Smolka, C.; Yue, S.; Krüger, M.; Fiorillo, C.; Vaquero, A.; Bober, E.; Braun, T. SIRT7-dependent deacetylation of NPM promotes p53 stabilization following UV-induced genotoxic stress. Proc Natl Acad Sci U S A. 2021, 118, e2015339118. [Google Scholar] [CrossRef] [PubMed]
  169. Lv, J.; Tian, J.; Zheng, G.; Zhao, J. Sirtuin7 is involved in protecting neurons against oxygen-glucose deprivation and reoxygenation-induced injury through regulation of the p53 signaling pathway. J Biochem Mol Toxicol. 2017, 31. [Google Scholar] [CrossRef]
  170. Sun, M.; Zhai, M.; Zhang, N.; Wang, R.; Liang, H.; Han, Q.; Jia, Y.; Jiao, L. MicroRNA-148b-3p is involved in regulating hypoxia/reoxygenation-induced injury of cardiomyocytes in vitro through modulating SIRT7/p53 signaling. Chem Biol Interact. 2018, 296, 211–219. [Google Scholar] [CrossRef]
  171. Yu, M.; Shi, X.; Ren, M.; Liu, L.; Qi, H.; Zhang, C.; Zou, J.; Qiu, X.; Zhu, W.G.; Zhang, Y.E.; Wang, W.; Luo, J. SIRT7 Deacetylates STRAP to Regulate p53 Activity and Stability. Int J Mol Sci. 2020, 21, 4122. [Google Scholar] [CrossRef]
  172. Olsen, E.A.; Kim, Y.H.; Kuzel, T.M.; Pacheco, T.R.; Foss, F.M.; Parker, S.; Frankel, S.R.; Chen, C.; Ricker, J.L.; Arduino, J.M.; Duvic, M. Phase IIb multicenter trial of vorinostat in patients with persistent; progressive; or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007, 25, 3109–15. [Google Scholar] [CrossRef]
  173. O'Connor, O.A.; Horwitz, S.; Masszi, T.; Van Hoof, A.; Brown, P.; Doorduijn, J.; Hess, G.; Jurczak, W.; Knoblauch, P.; Chawla, S.; Bhat, G.; Choi, M.R.; Walewski, J.; Savage, K.; Foss, F.; Allen, L.F.; Shustov, A. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. J Clin Oncol. 2015, 33, 2492–9. [Google Scholar] [CrossRef]
  174. Garcia-Manero, G.; Yang, H.; Bueso-Ramos, C.; Ferrajoli, A.; Cortes, J.; Wierda, W.G.; Faderl, S.; Koller, C.; Morris, G.; Rosner, G.; Loboda, A.; Fantin, V.R.; Randolph, S.S.; Hardwick, J.S.; Reilly, J.F.; Chen, C.; Ricker, J.L.; Secrist, J.P.; Richon, V.M.; Frankel, S.R.; Kantarjian, H.M. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008, 111, 1060–6. [Google Scholar] [CrossRef]
  175. Gu, S.; Hou, Y.; Dovat, K.; Dovat, S.; Song, C.; Ge, Z. Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia. Exp Hematol Oncol. 2023, 12, 23. [Google Scholar] [CrossRef] [PubMed]
  176. Maher, K.R.; Schafer, D.; Schaar, D.; Sabo, R.; Bandyopadhyay, D.; Grant, S. Pevonedistat plus belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome: A phase I multicenter study. JCO. 2023, 41, e19015–e19015. [Google Scholar] [CrossRef]
  177. Maher, K.R.; Shafer, D.; Schaar, D.; Bandyopadhyay, D.; Deng, X.; Wright, J.; Piekarz, R.; Rudek, M.A.; Harvey, R.D.; Grant, S. A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome. Cancer Chemother Pharmacol. 2025, 95, 24. [Google Scholar] [CrossRef] [PubMed]
  178. Li, L.; Osdal, T.; Ho, Y.W.; McDonald, T.; Chun, S.; Chu, S.; Lin, A.; Dos Santos, C.; Popa, M.L.; Gjertsen, B.T.; Chen, W.; Lain, S.; McCormack, E.; Bhatia, R. Pharmacological Inhibition Of The SIRT1 Deacetylase With The Small Molecule Inhibitor Tenovin-6 Enhances Ablation Of FLT3-ITD+ LSC In Combination With TKI Treatment. Blood. 2013, 122, 2685. [Google Scholar] [CrossRef]
Preprints 149561 g001
Figure 1. Division of histone deacetylases with particular reference to sirtuins (SIRTs) and their classes.
Figure 1. Division of histone deacetylases with particular reference to sirtuins (SIRTs) and their classes.
Preprints 149561 g001
Table 1. Roles of sirtuins (SIRTs) in AML.
Table 1. Roles of sirtuins (SIRTs) in AML.
Sirtuin
(SIRT)		 Class Main cell localization Potential signaling pathways impact and affected molecules Functions Level Probable role in AML Ref.
SIRT1 I Nucleus p53, c-Myc, USP22, FOXO1, FOXP1, STAT5, DOT1L, miR-9 Deacetylase Deacylase High Promoter 38, 39, 42, 50, 51, 52, 53, 55
SIRT2 I Cytosol
Nucleus (during mitosis)		 NAMPT, MAPK, VEGF, MRP1, ERK1/2, BCL-2, p53, Caspase-1, AKT/GSK3ß/ß-catenin, PI3K/AKT/mTOR, pentose-phosphate cycle, p21, cyclin E1, miR-140-5p, miR-145 Deacetylase Deacylase High Promoter 63, 64, 68, 69, 70, 71, 72, 73, 74, 75
SIRT3 I Mitochondria PTEN, MDM2, p53, cyclophilin D, IDH2, tricarboxylic acid cycle, Fatty acid oxidation, sumoylation, HES1, Notch1 Deacetylase Decrotonylase Low Undetermined/
Bi-directional		 78, 79, 80, 81, 84, 85
SIRT4 II Mitochondria Glutamine metabolism Deacetylase Deacylase
ADP-rybosil-transferase,		 Low (high according to some sources) Undetermined/
Bi-directional		 90, 92, 93
SIRT5 III Mitochondria BAX/BCL-2, oxidative phosphorylation Deacetylase Demalonylase Deglutarylase Desuccinylase No data Promoter 102,103,104,105, 108, 109, 111, 112
SIRT6 IV Nucleus NAMPT, NMNAT1, cyclin-CDK Deacetylase Deacylase
ADP-rybosil-transferase		 High Promoter 137, 143, 144, 145
SIRT7 IV Nucleus
Nucleolus		 NRF1, NPM1, p53 Deacetylase
Dessuccinylase		 Low Suppressor 144, 148, 161, 162, 164, 168
AML – acute myeloid leukemia, c-Myc – cellular myelocytomatosis oncogene, USP22 – ubiquitin-specific peptidase 22, FOXO1 – forkhead box protein O1, FOXP1 – forkhead box protein 1, STAT5 – signal transducer and activator of transcription 5, DOT1L – disruptor of telomeric silencing 1-like, miR-9 – microRNA-9, NAMPT – nicotinamide phosphoribosyltransferase, MAPK – mitogen-activated protein kinase, VEGF – vascular endothelial growth factor, MRP1 – multidrug resistance-associated protein 1, ERK1/2 – extracellular signal-regulated kinase 1 and 2, BCL-2 – B-cell lymphoma 2 protein, AKT – protein kinase B, GSK3ß – glycogen synthase kinase-3 beta, PI3K – phosphoinositide-3-kinase, mTOR – mammalian target of rapamycin, miR-140-5p – microRNA-140-5p, miR-145 – microRNA-145, PTEN – phosphatase and tensin homologue deleted on chromosome 10 (PTEN), MDM2 – mouse double minute 2 homolog, IDH2 – isocitrate dehydrogenase (NADP(+)) 2, HES – hairy and enhancer of split-1, Notch1 – neurogenic locus notch homolog protein 1, BAX – bcl-2-like protein 4, NMNAT1 – nicotinamide nucleotide adenylyltransferase 1, cyclin-CDK – cyclin-dependent kinase complex, NRF1 – nuclear respiratory factor 1, NPM1 – nucleophosmin 1.
Table 2. Selected sirtuin (SIRT) modulators.
Table 2. Selected sirtuin (SIRT) modulators.
Molecule Mechanism of action Targeted sirtuin
(SIRT)		 Additional mechanisms Reference
Selisistat (EX-527) Inhibitor SIRT1 Westerberg et al., 2015
MC3482 Inhibitor SIRT5 Polletta L et al., 2015
SIRT5 inhibitor 1 Inhibitor SIRT5 Wang et al., 2022
Tenovin-1 Inhibitor SIRT1
SIRT2
 - p53 activation
- Dihydroorotate dehydrogenase inhibitor		 Huang et al., 2019
Wan et al., 2021
Lain et al., 2008
Ladds et al., 2021
BZD9Q1 Inhibitor SIRT1
SIRT2
SIRT3		 - apoptosis and necrosis induction, G2/M cycle arrest Chen et Yeong, 2024
SIRT6-IN-2 (compound 5) Inhibitor SIRT6 - increase acetylation of H3K9
- increase glucose uptake in cultured cells		 Damonte et al., 2017
UBCS039 Activator SIRT6 - anti-inflammatory response
- oxidative stress alleviation		 Chen et Yeong, 2024
Jiao et al., 2022
4'-Bromo-resveratrol Inhibitor SIRT1
SIRT3		 - mitochondrial metabolic reprogramming George et al., 2019
JFD00244 Inhibitor SIRT2 - Nsp-16 inhibitor Shankar et al., 2020
Nicotinamide-d4
Nicotinamide-13C6
Nicotinamide-15N,13C3 		Inhibitors SIRT1 - NAD+ redox homeostasis Bitterman et al., 2002
Hwang et al., 2017
Z26395438 (compound 1) Inhibitor SIRT1 Gryniukova et al., 2023
Sirt1/2-IN-3 (compound PS9) Inhibitor SIRT1
SIRT2		 - p53 deacetylation blockade Cai et al., 2023
Sirt1/2-IN-2 (compound hsa55) Inhibitor SIRT1
SIRT2		 - p53 deacetylation blockade Cai et al., 2023
Antiproliferative agent-17 Inhibitor SIRT1
 - anticancer activity
- Gram+ bacteria inhibition		 Warda et al., 2022
SirReal1, SirReal2 Inhibitors SIRT2 Schiedel et al., 2016
SIRT1 activator 1(compound 3) Activator SIRT1 Yang et al., 2023
SIRT5 inhibitor 8 (compound 10) Inhibitor SIRT5 - anticancer potential Wang et al., 2023
3-aryl-mercapto-butyrylated peptide derivative Inhibitor SIRT2 Kalbas et al., 2022
SIRT5 Inhibitor 6 (2,4,5-trisubstituted pyrimidine derivative) Inhibitor SIRT5 - modulating sepsis
- AKI		 Mou et al., 2023
SIRT2-IN-12 (compound 3) (xanthone derivative) Inhibitor SIRT2 Mazur et al., 2024
SIRT5 inhibitor 9 (compound 14) Inhibitor SIRT5 - anticancer potential Wang et al., 2023
Mz325 Inhibitor SIRT2 - HDAC inhibitor Sinatra et al., 2023
HSP70/SIRT2-IN-2 (Compounds 1a) Inhibitor SIRT2 - HSP70 inhibitor
- anticancer activity		 Abbotto et al., 2023
Sirt1/2-IN-4 (compound PS3) Inhibitor SIRT1
SIRT2
SIRT3		 - potential anticancer activity
- blocks p53 deacetylation		 Cai et al., 2023
SIRT4-IN-1 (compound 69) Inhibitor SIRT4 Pannek et al., 2024
SIRT2/6-IN-1 (Compound 5) Inhibitor SIRT2
SIRT6		 - increases H3K9 acetylation
- increases glucose uptake
- reduces TNF-alfa secretion in cells		 Parenti et al., 2014
SIRT5 inhibitor 7 (compound 58) (2,4,5-trisubstituted pyrimidine derivative) Inhibitor SIRT5 - anti-inflammatory activity Mou et al., 2023
SIRT1/2/3-IN-1 (compound 10) Inhibitor SIRT1
SIRT2
SIRT3		 - potential anticancer
activity		 Li et al., 2020
H3K9 – 9th lysine residue of the histone H3 protein, Nsp-16 – non-structural protein 16, NAD+ – nicotinamide adenine dinucleotide; AKI – acute kidney injury, HDAC – histone deacetylases, HSP70 – 70 kilodalton heat shock proteins, TNF-alfa – tumor necrosis factor-alfa.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
bsky
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

Privacy Settings

© 2025 MDPI (Basel, Switzerland) unless otherwise stated